0001493152-18-015653.txt : 20181113 0001493152-18-015653.hdr.sgml : 20181113 20181113070151 ACCESSION NUMBER: 0001493152-18-015653 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TechCare Corp. CENTRAL INDEX KEY: 0001498067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 980663823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55680 FILM NUMBER: 181175016 BUSINESS ADDRESS: STREET 1: 1140 AVENUE OF THE AMERICAS, CITY: NEW YORK, STATE: X1 ZIP: 10036 BUSINESS PHONE: 972-3-750-3060 MAIL ADDRESS: STREET 1: 1140 AVENUE OF THE AMERICAS, CITY: NEW YORK, STATE: X1 ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: BREEDIT CORP. DATE OF NAME CHANGE: 20140106 FORMER COMPANY: FORMER CONFORMED NAME: PROGAMING PLATFORMS CORP DATE OF NAME CHANGE: 20100802 10-Q 1 form10-q.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission file number: 000-55680

TECHCARE CORP.
(Exact Name Of Registrant As Specified In Its Charter)

Delaware		68-0080601
(State of Incorporation)		(I.R.S. Employer Identification No.)

1140 Avenue of the Americas, New York, NY		10036
(Address of Principal Executive Offices)		(ZIP Code)

Registrant’s Telephone Number, Including Area Code: + (972) 3 750-3060 or (646) 380-6645

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the defnitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer [ ]		Accelerated filer [ ]
	Non-Accelerated filer [X]		Smaller reporting company [X]
			Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

On November 12, 2018, the Registrant had 29,949,096 shares of common stock outstanding.

TABLE OF CONTENTS

Item	Description	Page

	PART I - FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS (UNAUDITED).
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations and Comprehensive loss	4
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Unaudited Financial Statements	6
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS.	18
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	24
ITEM 4.	CONTROLS AND PROCEDURES.	25

	PART II - OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS.	26
ITEM 1A.	RISK FACTORS.	26
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.	26
ITEM 3.	DEFAULT UPON SENIOR SECURITIES.	26
ITEM 4.	MINE SAFETY DISCLOSURE.	27
ITEM 5.	OTHER INFORMATION.	27
ITEM 6.	EXHIBITS.	27
	SIGNITURES.	28

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TechCare Corp.

Condensed Consolidated Balance Sheets

As of September 30, 2018 and December 31, 2017

(Unaudited)

	September 30, 2018			December 31, 2017
Assets
Current assets:
Cash and cash equivalents	$	384,495		$	589,818
Accounts receivables		173,626			3,318
Inventory		156,240			41,445
Other receivables		244,212			105,818
Total current assets		958,573			740,399

Non-current assets:
Severance pay fund		21,564			13,764
Long-term deposits		11,745			12,287
Property and equipment, net		133,365			95,984
Total non-current assets		166,674			122,035
Total assets	$	1,125,247		$	862,434

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	252,376		$	106,362
Refund liability		107,460			-
Note payable		84,719			88,751
Option liability		-			132,470
Total current liabilities		444,555			327,583

Non-current liability:
Liability for severance pay		27,642			23,422
Total liabilities		472,197			351,005

Commitments

Stockholders’ equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2018 and December 31, 2017		-			-
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 29,949,096 and 25,835,401 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		2,995			2,584
Accumulated other comprehensive income		111,780			104,777
Additional paid-in capital		8,564,286			6,945,151
Stock to be issued		60,000			30,000
Accumulated deficit		(8,086,011	)		(6,571,083	)
Total stockholders’ equity		653,050			511,429

Total liabilities and stockholders’ equity	$	1,125,247		$	862,434

The accompanying notes are an integral part of these condensed consolidated financial statements.

TechCare Corp.

Condensed Consolidated Statements of Operations

and Comprehensive loss

For the Nine and Three-Months Periods Ended September 30, 2018 and 2017

(Unaudited)

	For the nine			For the nine			For the three			For the three
	months ended			months ended			months ended			months ended
	September 30, 2018			September 30, 2017			September 30, 2018			September 30, 2017
				Restated						Restated
Revenues		188,809			-			90,367			-
Cost of revenues		128,842			-			71,224			-
Gross profit		59,967			-			19,143			-

Research and development expenses		191,316			263,268			143,400			83,030
Change in fair value of option liability		(132,470	)		182,720			-			(93,430	)
Marketing, General and administrative expenses		1,489,784			2,082,658			522,864			398,880
Operating loss		1,488,663			2,528,646			647,121			388,480

Financial expenses (income), net		26,265			(24,495	)		9,110			(5,304	)

Net loss	$	1,514,928			2,504,151			656,231		$	383,176

Net loss per common stock:
Basic	$	(0.05	)	$	(0.12	)		(0.02	)	$	(0.02	)
Diluted	$	(0.05	)	$	(0.12	)		(0.02	)	$	(0.02	)

Weighted average number of common stock outstanding:
Basic		31,709,944			21,722,199			32,529,717			21,752,409
Diluted		31,807,036			21,722,199			32,529,717			22,018,967

Comprehensive loss:
Net loss		1,514,928			2,504,151			656,231			383,176
Other comprehensive expense (income) attributable to foreign currency translation		(7,003	)		(10,058	)		8,702			2,344
Comprehensive loss		1,507,925			2,494,093			664,933			385,520

The accompanying notes are an integral part of these condensed consolidated financial statements.

TechCare Corp.

Condensed Consolidated Statements of Cash Flows

For the Nine-Months Periods Ended September 30, 2018 and 2017

(Unaudited)

	For the nine			For the nine
	months ended			months ended
	September 30, 2018			September 30, 2017
				Restated
Cash flows from operating activities:
Net loss	$	(1,514,928	)	$	(2,504,151	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		(9,329	)		10,193
Stock issued in relation to consulting services		-			70,964
Change in fair value of option liability		(132,470	)		182,720
Stock-based compensation		27,544			1,222,920
Changes in cash attributed to changes in operating assets and liabilities:
Other receivables and prepaid expenses		(310,877	)		7,055
Accounts payable and accrued expenses		151,413			(60,512	)
Liability for severance pay		(6,614	)		5,229
Refund liability		107,088			-
Inventory		(120,978	)		-
Net cash used in operating activities		(1,809,151	)		(1,065,582	)

Cash flow from investing activities:
Severance pay fund		3,485			(1,592	)
Purchase of fixed assets		(31,999	)		(4,170	)
Investment in long-term deposit		-			(6,059	)
Net cash used in investing activities		(28,514	)		(11,821	)

Cash flow from financing activities:
Proceeds from issuance of common stock		1,592,000			878,250
Proceeds from stock to be issued		30,000			-
Net cash provided by financing activities		1,622,000			878,250

Effect of exchange rates on cash and cash equivalents		10,342			8,394
Decrease in cash and cash equivalents		(205,323	)		(190,759	)

Cash and cash equivalents - beginning of period		589,818			275,041
Cash and cash equivalents - end of period	$	384,495		$	84,282

Non-cash financing activity during the period:
Issuance of common stock and warrants				$	194,995

The accompanying notes are an integral part of these condensed consolidated financial statements.

TechCare Corp.

Notes to Unaudited Financial Statements

September 30, 2018 (Unaudited)

NOTE 1: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Nature of operations

TechCare Corp. (“Techcare” or the “Company”), formally known as BreedIT Corp. (“BreedIt”) was incorporated under the laws of the State of Delaware on May 26, 2010. The Company’s common stock is traded in the United States on the OTCQB Market under the ticker symbol “TECR”.

On February 8, 2016, the Company signed a Merger Agreement with Novomic Ltd. (“Novomic”), a private company incorporated under the laws of the State of Israel. The closing of the Merger took place on August 9, 2016 pursuant to which Novomic became a wholly-owned subsidiary of the Company. The Merger was structured as a reverse Merger.

Novomic was incorporated as a private company in Israel in 2009. Since inception, Novomic has been a technology company engaged in the design, development and commercialization of a unique delivery platform utilizing vaporization of various natural compounds for multiple health, beauty and wellness applications. Novomic’s delivery platform is proprietary and patented.

Novomic’s first product is Novokid® - an innovative home use device which vaporizes a natural, plant-based, pesticides and silicone-free compound that effectively treats head lice and eggs. The Novokid® kit includes a vaporizer, treatment capsules and treatment cap alongside ancillary components. Novokid® is currently being sold in Israel and the Netherlands.

Novomic is currently working on the research and development of future product offerings for its delivery platform, including Shine, a revolutionary cosmetic device for the treatment and rejuvenation of the hair and scalp.

Going Concern

During the nine months period ended September 30, 2018, the Company had a comprehensive loss of approximately $1.5 million. As of September 30, 2018, the Company had accumulated losses of approximately $8 million.

Based on the projected cash flows and Company’s cash balances as of September 30, 2018, Company’s management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue advancing its activities including the development, manufacturing and marketing of its products for a period of at least 12 months from the date of issuance of these financial statements. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

Management’s plans include the continued commercialization of the products, continue taking cost reduction steps and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to reduce activities, curtail or cease operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

B. Summary of significant accounting policies

The accounting policies adopted are consistent with those of the previous financial year.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and condensed footnotes have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“GAAP”), for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for fair statement of results for the interim periods presented have been included. The results of operations for the nine and the three months ended September 30, 2018 are not necessarily indicative of the results to be expected for the year or for other interim periods or for future years. The consolidated balance sheet as of December 31, 2017 is derived from audited financial statements as of that date; however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on April 2, 2018.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of TechCare, and its subsidiary, Novomic. All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

Effective January 1, 2018, the Company adopted the new accounting standard related to the recognition of revenue in contracts with customers. Since the Company had no revenues prior to January 1, 2018, the new standard had no impact on revenues and results of operations for prior periods.

The Company derives revenues from sales of its product Novokid directly or indirectly through its distributors in the Netherlands and in Israel.

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer.
	●	Identification of the performance obligations in the contract.
	●	Determination of the transaction price.
	●	Allocation of the transaction price to the performance obligations in the contract.
	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

Revenue is measured as the amount of consideration expected to receive in exchange for transferring goods to the end customer or to the distributor.The Company also considers products that might be returned mostly based on the terms stipulated in the agreements with its distributors.The Company recognize the amount received or receivable that is expected to be returned as a refund liability,representing its obligation to return the clients’ consideration.

The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.

Revenue from products are recognized when the customer or the distributor has obtained control of the goods (for the Company’s current arrangements, this is at the point in time) based on the shipping terms. The Company recognizes revenue on sales to distributors upon shipment of the goods, when the distributor has economic substance apart from the Company and the distributor is considered the principal for the transaction with the end-user client.

NOTE 2: NEW ACCOUNTING PRONOUNCEMENTS

Accounting Pronouncements Adopted in Current Period

In May 2014, and in following related amendments, the Financial Accounting Standards Board (the “FASB”) issued a new comprehensive revenue recognition guidance on revenue from contracts with customers ( the “Standard”) that will supersede the current revenue recognition guidance. The Standard provides a unified model to determine when and how revenue is recognized. The core principle of the Standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements since the Company had no revenues prior to 2018.

In January 2016, the FASB issued an Accounting Standards Update (an “ASU”) which changes to the current measurement model primarily affects all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Under the new ASU equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) with readily determinable fair values will be measured at fair value through earnings. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements.

In November 2016, the FASB issued an ASU which requires entities to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements.

In June 2018, the FASB issued an ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which previously included share-based payments to employees only) to include share based payments issued to nonemployees for goods or services, with certain exceptions. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 commencing July 1, 2018, with no impact on its consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued a new ASU which revises lease accounting guidance. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability for all leases, other than leases that meet the definition of a short-term lease. The liability and the right-of-use asset arising from the lease will be measured as the present value of the lease payments. In addition, this guidance requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. The new standard is effective for fiscal year beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach, with certain practical expedients. The Company is currently evaluating the impact of the adoption of the new lease accounting guidance on its consolidated financial statements.

NOTE 3: RESTATEMENT OF 2017 CONDENSED CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS

As discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, during the preparation of the 2017 annual financial statements, the Company became aware of misstatements in its condensed consolidated financial statements for the quarter ended March 31, 2017, the six months ended June 30, 2017, and the nine months ended September 30, 2017, that were included in each of the Company’s 2017 Form 10-Qs. The misstatement stemmed from an erroneous recording of additional stock compensation expense of $943,901 during the three months ended March 31, 2017 related to certain fully vested awards that were granted in December 31, 2016, and were properly fully expensed in 2016. As a result, the Company’s previously reported net loss for each of the three aforementioned periods in 2017 was overstated by this amount. The Board of Directors and the Company concluded that due to this error the condensed consolidated financial statements for each of these periods was materially misstated and should be restated (the Restatement).

The Restatement also corrects certain other misstatements during the 2017 interim periods, including (i) an error related to the accounting for advances to suppliers that were previously expensed that impacted the quarters ended June 30, 2017, and September 30, 2017, and (ii) errors in the classification of certain expenses within the consolidated statements of operations and comprehensive loss which impacts classification only and does not impact the total net loss or comprehensive loss reported for any of the periods.

The Restatement does not result in a change to the Company’s previously reported total amounts of net cash flows from operating activities, investing activities, or financing activities. There was no impact to net change in cash and cash equivalents for any previously reported periods. Certain corrections of classifications within the operating cash flow section were impacted by the Restatement.

Condensed consolidated balance sheet as of September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Assets
Current assets:
Cash and cash equivalents	$	84,282						84,282
Other receivables		160,620			29,755			190,375
Total current assets		244,902			29,755			274,657

Non-current assets:
Severance pay fund		10,403						10,403
Long-term deposit		12,071						12,071
Property and equipment, net		99,744						99,744
Total non-current assets		122,218						122,218
Total assets	$	367,120			29,755			396,875

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	137,780						137,780
Option liability		182,720						182,720
Note payable		87,192						87,192
Total current liabilities		407,692						407,692

Non-current liability:
Liability for severance pay		21,184						21,184
Total liabilities		428,876						428,876

Commitments

Stockholders’ equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017		-						-
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017		2,177						2,177
Accumulated other comprehensive income		107,061						107,061
Additional paid-in capital		6,970,542			(943,901	)		6,026,641
Stock to be issued		48,964						48,964
Accumulated deficit		(7,190,500	)		973,656			(6,216,844	)
Total capital deficiency		(61,756	)		29,755			(32,001	)
Total liabilities and capital deficiency	$	367,120			29,755			396,875

Condensed consolidated statement of operations and comprehensive loss for the nine month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		872,874			(609,606	)		263,268
Change in fair value of option liability		182,720						182,720
Marketing, general and administrative expenses		2,441,860			(359,202	)		2,082,658
Operating loss		3,497,454			(968,808	)		2,528,646

Financial income, net		24,495						24,495

Loss before income taxes		3,472,959			(968,808	)		2,504,151
Tax expenses		4,848			(4,848	)		-
Net loss	$	3,477,807			(973,656	)		2,504,151

Net loss per common stock:
Basic	$	(0.16	)		0.04			(0.12	)
Diluted	$	(0.16	)		0.04			(0.12	)

Weighted average number of common stock outstanding:
Basic		21,722,199						21,722,199
Diluted		21,722,199						21,722,199

Comprehensive loss:
Net loss		3,477,807			(973,656	)		2,504,151
Other comprehensive income attributable to foreign currency translation		10,058						10,058
Comprehensive loss		3,467,749			(973,656	)		2,494,093

Condensed consolidated statement of operations and comprehensive loss for the three month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		131,765			(48,735	)		83,030
Change in fair value of option liability		(93,430	)					(93,430	)
Marketing, general and administrative expenses		361,342			37,538			398,880
Operating loss		399,677			(11,197	)		388,480

Financial income, net		5,304						5,304

Loss before income taxes		394,373			(11,197	)		383,176
Tax expenses		-						-
Net loss	$	394,373			(11,197	)		383,176

Net loss per common stock:
Basic	$	(0.018	)		-			(0.018	)
Diluted	$	(0.022	)		-			(0.022	)

Weighted average number of common stock outstanding:
Basic		21,752,409						21,752,409
Diluted		22,018,967						22,018,967

Comprehensive loss:
Net loss		394,373			(11,197	)		383,176
Other comprehensive expense attributable to foreign currency translation		2,344						2,344
Comprehensive loss		396,717			(11,197	)		385,520

NOTE 4: STOCKHOLDERS’ EQUITY

Share capital

During the nine months ended September 30, 2018, the Company entered into several agreements, under which the Company raised an aggregate amount of $ 1,622,000, as follows:

	a)	1,291,990 shares of its common stock at a purchase price of $0.387 for a total consideration of $500,000 and warrants to purchase up to 645,995 stock with an exercise price of $0.387, exercisable until June 30, 2018. The warrants expired on June 30, 2018.

	b)	1,033,592 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $400,000, and warrants to purchase up to 516,796 stock with an exercise price of $0.387, exercisable until September 30, 2018. The warrants expired on September 30, 2018.

	c)	108,527 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $42,000, and warrants to purchase up to 70,000 stock with an exercise price of $0.60, exercisable until June 17, 2019.

Investment agreements signed during the three months ended September 30, 2018:

	d)	645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until June 27, 2019.

	e)	645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	f)	129,199 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $50,000, and warrants to purchase up to 83,333 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	g)	258,398 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $100,000, and warrants to purchase up to 166,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	h)	77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 shares of common stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet issued the shares of common stock and, therefore, recorded stock to be issued in the amount of $30,000 in the consolidated financial statements.

	i)	77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet received the investment proceeds and therefore had not issued the shares of common stock for such investment.

Stock-Based Compensation to employees and directors

Stock based awards are accounted for using the fair value method in accordance with ASC 718, Shared Based Payment. The Company’s primary type of stock-based compensation consists of stock options to directors, employees and officers. The Company uses Black-Scholes option pricing model in valuing options.

During the nine months ended September 30, 2018 the Company had not granted any options to employees and directors.

During March 2017, the Company granted to certain employees options to purchase 869,596 of the Company’s common stock for an exercise price of $0.0001. The options granted were fully vested on the date of the grant and exercisable into the Company’s common stock at a 1:1 ratio for 2.5 years from the date of the grant.

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2.5-5
Dividend yield	-

The Company based the risk-free interest rate on the U.S. Treasury yield curve. The expected term in years represents the period of time that the awards granted are expected to be outstanding. The assumption for dividend yield is zero because the Company has not historically paid dividends nor does it expect to do so in the foreseeable future. The volatility was based on the historical stock volatility of several peer companies, as the Company has limited trading history to use the volatility of its own common stock.

A summary of the stock option activity for employees and directors for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		2,640,334		0.0001
Granted		-		-
Options outstanding at September 30, 2018		2,640,334		0.0001
Options exercisable at September 30, 2018		2,640,334		0.0001

Stock-based compensation expenses related to employee awards, included in the Company’s statements of operations and comprehensive loss, were allocated as follows:

	Nine months ended September 30, 2018		Nine months ended September 30, 2017
			Restated (see note 3)
Research and development expenses	$	-		103,795
Marketing ,general and administrative		-		1,119,125
	$	-		1,222,920

Stock-Based Compensation to non-employees – Options and Warrants

The Company early adopted ASU 2018-07 commencing July 1, 2018, with no impact on its consolidated financial statements. Prior to the adoption of ASU 2018-07 stock options issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the options. The fair value of the options granted were measured on a final basis at the end of the related service period and were recognized over the related service period using the straight line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, over the requisite service period, which is the vesting period of the respective award.

In the second quarter of 2018, as part of consulting agreements, the Company granted options to non-employees, as follows:

	1)	83,393 options exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on December 1, 2018, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

	2)	83,393 options to a related party exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on January 1, 2019, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

	3)	436,349 options to a related party exercisable to purchase 436,349 shares of common stock of the Company, at an exercise price of $0.387 per option. The options will be vested in accordance with the following vesting periods: 33.33% of the options will be exercisable on January 1, 2019, and the remaining 66.67% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 8 quarters.

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	2.65%-2.85	%
Expected shares price volatility	70	%
Expected option term (years)	5
Dividend yield	-

During January 2017, as part of a consulting agreement, the Company granted to a non-employee warrants exercisable to purchase 100,000 of the Company’s common stock at an exercise price of $1.50 per warrant exercisable for a period of 24 months commencing on the date of the agreement, fully vested on the date of the grant.

During March 2017, the Company granted to a non-employee options to purchase 521,065 of the Company’s common stock for an exercise price of $0.0001. The options granted were fully vested on the date of the grant and exercisable into the Company’s common stock at a 1:1 ratio for 5 years from the date of the grant.

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2-5
Dividend yield	-

A summary of the stock option activity related to non-employees, for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		621,065		0.2416
Granted		603,135		0.2800
Options outstanding at September 30, 2018		1,224,200		0.2605
Options exercisable at September 30, 2018		621,065		0.2416

Stock-based compensation expenses in the amount of $27,544 included in the Company’s statements of operations and comprehensive loss for the nine months period ended September 30, 2018 recorded in marketing, general and administrative.

NOTE 5: OEM DISTRIBUTION AGREEMENT

On June 23, 2017, the Company entered into an OEM agreement (the “OEM Agreement”) with a medical device and wellness applications company based in the United States (the “OEM Distributor”), according to which the OEM Distributor will manufacture, distribute and sell the Company’s Novokid head lice treatment products in the United States, Canada, Brazil, Argentina, Costa Rica and Colombia, all on an exclusive basis, pursuant to and in accordance with the terms and conditions set forth in the OEM Agreement, including minimum royalties commitments. The OEM Distributor will be solely responsible for obtaining and maintaining the approval from the US Food and Drug Administration (the “FDA”) and shall bear all costs related to such approval. The Company, through its OEM Distributor, has been communicating with the FDA regarding Novokid’s designation as a medical device. An Application to the FDA Office of Combination (OCP division) is under preparation.

As of the date of these financial statements, an FDA approval was not obtained, hence, the Company did not generate any revenues from the OEM agreement.

As part of the OEM Agreement, the OEM Distributor paid a royalty advance of $10,000 and also an amount of $140,000 which is held in an escrow account, until the Company completes certain milestones, as described in the OEM Agreement. As of September 30, 2018, the milestones have not been achieved.

Also, as part of the OEM Agreement, the Company granted the OEM Distributor an option to purchase up to 9.09% of the Company’s common stock for a total consideration of up to $900,000,exercisable until January 15, 2018.

The fair value of the option as of June 23, 2017 (initial recognition) amounted to $432,518.The key assumptions used in the options’ valuation was as follows:

Risk-free interest rate	1.14	%
Expected shares price volatility	70	%
Expected option term (years)	0.56
Dividend yield	-

The fair value of the option as of December 31, 2017 amounted to $132,470.The key assumptions used in the options’ valuation was as follows:

Risk-free interest rate	1.28	%
Expected shares price volatility	70	%
Expected option term (years)	0.04
Dividend yield	-

The option expired on January 15, 2018.

NOTE 6: INCOME TAXES

a. Basis of taxation

The Company and its subsidiary are taxed under the domestic tax laws of the jurisdiction of incorporation of each entity (United States and Israel).

b. Carryforward Tax Losses

Carryforward Tax Losses of the US Company as of September 30, 2018 amounted to approximately $0.4 million. Carryforward Tax Losses of the Israeli subsidiary amounted to approximately $5.1 million. A full valuation allowance was created against these carry forward tax losses since the realization of any future benefit from these net operating losses cannot be sufficiently assured at September 30, 2018.

c. Corporate tax rates

The regular corporate tax rate in Israel in 2017 is 24% and 23% in 2018.

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “TCJA”), which among other reduces the federal corporate tax rate from 35% to 21%, effective January 1, 2018.

The Company has no impact of the TCJA on these condensed consolidated financial statements.

NOTE 7: LOSS PER SHARE

Loss per share is based on the loss that is attributed to the stockholders holding common stock, divided by the weighted average number of common stock in issue during the period.

For purposes of the calculation of the diluted loss per share, the Company adjusts the weighted average number of common stock using the treasury stock method assuming conversion of all of the dilutive potential stock. The potential stock are taken into account only if their effect is dilutive (increases loss per share).

NOTE 8: FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amount of the Company’s financial instruments, including cash equivalents, current assets, accounts payable and accrued liabilities and notes payables approximate their fair value, due to their short term in nature and their carrying amounts approximates the amounts expected to be received or paid.

A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The Company accounts for option liability as Level 3 since its inputs are unobservable inputs for the liability.

The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:

	2018			2017
	US dollar			US dollar
Fair value as of January 1	$	132,470			-
Change in fair value recognized in statement of operations and comprehensive loss		(132,470	)		276,150
Fair value as of September 30	$	-			276,150

NOTE 9: RELATED PARTIES

	(a)	On June 28, 2018 the Company entered into a subscription agreement with an investor, pursuant to which the Company will issue 645,995 shares of its common stock at a purchase price of $0.387 for a total consideration of $250,000 and warrants to purchase up to 416,667 stock with an exercise price of $0.60, exercisable until June 28, 2019. In August 2018, the funds were received and the shares of common stock were issued.

	(b)	On August 8, 2018 the Company entered into subscription agreements with several investors who are related parties, pursuant to which the Company issued 904,393 shares of its common stock at a purchase price of $0.387 for a total consideration of $350,000 and warrants to purchase up to 583,334 stock with an exercise price of $0.60, exercisable until August 7, 2019.

	(c)	On July 16, 2018, the Board of Directors of the Company has appointed Mr. Doron Biran as the new Chief Executive Officer of the Company and its wholly-owned subsidiary Novomic. Pursuant to the service agreement (the “Agreement”) signed with Mr, Biran, Mr. Biran will receive a monthly compensation of NIS 52 thousand (approximately $14.3 thousand) plus VAT. In the event of a capital raise exceeding $1,000 thousand Mr. Biran will be entitled to compensation increase to a total of NIS 65 thousand (approximately $17.9 thousand). Furthermore, upon the earlier of either 24 months from the effective date of the Agreement, or a capital raise exceeding $5,000 thousand and listing of the Company on the Nasdaq Stock Market, Mr. Biran shall become an employee of the Company and shall receive a base salary of NIS 60 thousand as well as NIS 5 thousands for automobile expenses (approximately $16.5 thousand) and other customary social benefits.

		Pursuant to the Agreement, Mr. Biran is entitled to options to purchase 870,958 common stock of the Company (the “Options”). The Options shall vest over a period of four years in quarterly increments, commencing on June 11, 2018, subject to continued provision of services by Mr. Biran in accordance with the Agreement. The Options shall accelerate and become fully vested in the event of a merger or acquisition of the Company at an evaluation exceeding $50 million or in the event that the Company’s traded value exceeds $50 million (each, “Acceleration Event” and together “Acceleration Events”), provided that Mr. Biran provided his services to the Company for a period of at least 12 months prior to the Acceleration Event. The exercise price of each Option shall be $0.279, equal to the volume weighted average price of the Company’s common stock during a 30 days’ period prior to the signing of Mr. Biran’s services Agreement. As of the date of the report Options were not granted yet.

NOTE 10: SUBSEQUENT EVENT

On October 28, 2018, the Company entered into an amendment to the subscription agreement mentioned in note 4e (the “Amendment”). Pursuant to the Amendment, the investor has increased its initial investment by an additional sum of $250,000 to a total investment of $500,000 and is to be issued a total of 1,915,708 shares of common stock at a price per share of $0.261, out of which 645,995 shares of common stock were issued in August 2018. In addition, the investor was issued additional warrants to purchase up to 416,667 shares of common stock with an exercise price of $0.6, exercisable until October 27, 2019. The funds were received in November 2018.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

FORWARD-LOOKING STATEMENTS

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Certain statements that the Company may make from time to time, including all statements contained in this Form 10-Q that are not statements of historical fact, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the safe harbor provisions set forth in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “will,” “should,” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new product launches, market position and expenditures. The Company assumes no obligation to update any forward-looking statements. Additional information concerning factors which could cause differences between forward-looking statements and future actual results is discussed under the heading “Risk Factors” in the Company’s Annual report on Form 10-K as filed with the SEC on April 2, 2018. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help you understand our historical results of operations during the periods presented and our financial condition for the periods ended September 30, 2018 and 2017. This MD&A should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements for the years ended December 31, 2017 and 2016.

Overview and Recent Developments

We are a technology company engaged in the design, development and commercialization of a unique delivery platform utilizing vaporization of various natural compounds for multiple health, beauty and wellness applications. Novomic’s delivery platform is proprietary and patented.

Our current product offering includes Novokid® - an innovative home use device which vaporizes a natural, plant-based, pesticides and silicone-free compound that effectively treats head lice and eggs. Following our soft launch of Novokid® in the Netherlands, we expanded our distribution network and launched Novokid in Israel during late May 2018 through Super Pharm, Israel’s largest and leading drugstore chain. The launch was accompanied by a radio and digital brand awareness and marketing campaign and supported by Meditrend, our Israeli distributor, specializing in health and wellness products while representing leading brands.

During the following months, we will work to expand our sales points to additional drugstore chains, pharmacies, department stores, HMOs, various online outlets, and the like.

As we remain focused on increasing our global footprint and expanding our distribution network, we showcased Novokid® and met potential distributors and partners at CPhI Worldwide, a renowned and leading pharma tradeshow held in Madrid during October 2018.

We are also working on erecting an automated production line which is expected to ramp up our manufacturing capacity while reducing its costs.

In July 2018, our board of directors has appointed Mr. Doron Biran as the new chief executive officer of the Company and its wholly-owned subsidiary Novomic. Mr. Biran replaced Mr. Zvi Yemini, our chairman of the board of directors, who served as our chief executive officer of the Company and its wholly-owned subsidiary Novomic since June 2018. In September 2018, we appointed Mr. Nir Shemesh as the new chief financial officer of the Company and its wholly owned subsidiary Novomic. Mr. Shemesh replaced Tzahi Geld who had served as chief financial officer of the Company since July 2017.

As of the date hereof, we have limited operations and revenues from our business operations. There is substantial doubt that we can continue as a going concern and an on-going business for the next twelve months without the success of our business operations which foresees the generation of revenues throughout 2018. Before we enter the U.S. market, we will need to secure approval from the FDA which will take approximately 12-24 months.

We project that we will need to raise up to $2,000,000 during the next 12 months in order to successfully implement our business plan, of which there can be no assurance. Failure to obtain this necessary capital at acceptable terms, if at all, when needed, may force us to delay, limit, or terminate our products development efforts and secure regulatory approvals and would adversely impact our planned research and development efforts in connection with the Company’s future products, which may make it more difficult for us to attain profitability.

Our Treatment Solutions

Novokid – Natural, Plant-based and Effective Lice Treatment

Parents and children exposed to head lice are now forced to use standard over-the-counter, or OTC, treatments that are toxic, often ineffective, time consuming and expensive. According to the Journal of Medical Entomology, 98% of lice have developed resistance to existing treatments in the US and they have now referred to as “super-lice”. Most current treatments contain pesticides, alcohol or silicone, which are all associated with a wide variety of hazardous side effects.

Novokid is a non-pesticide, natural, plant-based and eco-friendly solution that eliminates lice and super lice by a 10 minute dry treatment. This compares with current treatments that required 20-40 minutes of shampooing and daily combing. Our treatment is fast, dry, clean, and easily administered at home or on the go. Novokid can also be used as a maintenance and preventative treatment if used regularly.

Shine – Natural Haircare rejuvenation

Shine uses cold vaporization and a proprietary formulation to clean, treat and improve the appearance of the hair and scalp. In addition to removing the residue of products, the treatments will balance the hair’s pH levels, add body and shine, define curls, and strengthen and protect hair from further damage. Like our solution for lice, users simply put a Shine capsule in the compressor, place the attached cap on their head and sit for a 10-minute treatment. There is no need to rinse or shampoo following the treatment.

The global hair care market is estimated to be in excess of $80 billion per annum and we are looking to establish a presence in the home treatment niche. To that end, we are in the process of expanding the Shine treatment product line to include formulations for the needs of specific hair types, such as dry, curly, colored, and over-processed hair.

Recent Developments and Plans

Our current and future products are all based on the Platform which was developed over a period of seven years. During the past 18 months, we have achieved the following:

	●	Performed extensive market research for the lice treatment/prevention market;

	●	Completed product development of Novokid, which included finalization of commercial design of vaporizer, capsules and head cap, optimizing the product efficiency, negotiating and finalizing the product supply chain across various suppliers;

	●	Received the Israeli Ministry of health approval, or AMAR, to market our Novokid head lice treatment products in Israel;

	●	Attained ISO 9001 certification;

	●	Obtained CE approval for Novokid, classified as a Class I medical device;

	●	Obtained recommendations from leading senior pediatrics;

	●	Opened Company headquarters offices in Israel’s Rosh Ha’ayin Industrial Park;

	●	Entered into an Original Equipment Manufacturer, or OEM, Agreement, which we refer to as the OEM Agreement, according to which the OEM distributor will manufacture, distribute and sell the Company’s Novokid head lice treatment products, in the United States, Canada, Brazil, Argentina, Costa Rica and Colombia, all on an exclusive basis;

	●	Entered into a distribution agreement with an exclusive distributor of our Novokid product line in the Netherlands;

	●	Entered into a distribution agreement with an exclusive distributor of our Novokid product line in Israel;

	●	Contracted and set up production facilities in China and Israel; and

	●	Showcased Novokid® in CPhI Madrid, the world’s leading pharma tradeshow, held in Madrid, Spain, during October 2018.

During the next 12-18 months, we plan to focus our efforts on the following:

	●	Showcasing Novokid® and Shine and meet potential distributors and partners in multiple tradeshows around the world;

	●	Finalizing additional distribution, OEM and JV agreements with well-known distributes and manufacturers, in Israel and throughout the world;

	●	Erecting automated production and assembly lines;

	●	Reduction of manufacturing costs;

	●	Finalizing the development and commercialization of Shine, the Company’s hair treatment devices exploiting our proprietary vapor based delivery platform;

	●	Obtain the approval of the FDA for Novokid, by and through our OEM distributor;

	●	Obtain CE and FDA approvals for Shine;

	●	Complete preparations for mass production by launching an automated capsule production line;

	●	Presenting the platform and its application in leading conferences around the globe; and

	●	Developing our dermatology and pests control applications, based on our Platform.

We may be required to obtain additional regulatory approvals for our head lice treatment platform and any future products. If unable to receive regulatory approval or commercialize our product candidates, our business will be adversely affected. CE approval is required for the marketing, distributing and sale of our products in the EU, whereas FDA approval is required for such marketing, distributing and sale in the United States. In the event that our products are to be sold in certain territories requiring additional regulatory approvals, such approvals will need to be obtained by us or by our distributors.

Sales and Marketing

While the vaporizer for both Novokid and Shine is designated to be a one-time purchase, the head cap and the capsules, will be sold separately based on the razor/razor-blade business model. Based on our estimates, which we believe are both reasonable and conservative, our target customers are expected to purchase between 12-16 capsule units per year. Therefore, we estimate that the majority of our revenues will be generated in the future based on capsules sales for both Novokid and Shine products.

The Company plans to focus its initial sales and marketing efforts on the European Union where CE approval was obtained in Q3 2017, and once FDA approval for the Novokid product is received, also the United States.

In order to achieve our intended global footprint and market presence, we plan to base our primary distribution method on the distribution model, in which the distributer will sell our products under our name and branding. In specific instances, we will consider implementing the OEM model, in which the distributer will sell our products under a co-branding arrangement. We believe that these models will reduce our marketing costs to a minimum while starting to generate revenues to support our research and development efforts for utilizing our technological platform to expand our product line.

The Company also plans to market and advertise its products through implementing an omni-channel strategy, both through online and retail sales outlets, which we believe will present a huge opportunity for generating sales and market acceptance.

Production

We manufacture our products through third party manufacturers in Israel and China. The Novokid vaporizer is manufactured in China by a local manufacturer which also handles assembly, integration and quality assurance for the vaporizer and manufactures the cap and the ancillary components of the Novokid Kit. The Novokid treatment capsules are manufactured and filled in Israel by third party contractors. We are working with industry experts to erect an automated production and assembly line, which we expect to increase our manufacturing capacity as well as reduce its costs.

Research and Development

We incurred approximately $696 thousand on research and development during the past two years. During this period, the Company completed the development of both the Novokid and Shine products, which included finalization of commercial design of the compressor, capsules and head cap and optimizing the products efficiency.

We plan to build upon the research and development achievements we had with the completion of the Novokid product for head lice treatment as the basis to expand our variety of treatments and solutions, which will also be based on the developed Platform and the knowledge we gained during the past two years.

We are working on a new and proprietary capsule (patent-pending) which will enable a wider variety of future applications for our delivery platform.

Intellectual Property

Due to the importance of patents, we have devoted significant efforts and resources and will continue to invest resources in strengthening our patent portfolio. Below is the list of patents registered by the Company to date:

Patents	Each patent’s relevance to the program	Date and status of registration

EP 2 438 830 B1	Treating lice with gaseous compounds in airtight space.	Approved on July 16, 2014
US 9/307820 B2	Treating lice with gaseous compounds in airtight space.	Approved on April 12, 2016
US 15/438842	Treating an object with gaseous compounds in an airtight space.	February 22, 2017 *
US 62661868	A capsule for the vaporization of liquid	April 24, 2018 *

* Under approval process

We plan to expand our existing patents portfolio to encompass additional applications.

Results of Operations during the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017

During the Nine months ended September 30, 2018, we generated approximately $189 thousand in revenues, compared to no revenues in the Nine months ended September 30, 2017. Our revenues are derived from the launch of Novokid® in the Netherlands and in Israel.

Our research and development expenses during the nine months ended September 30, 2018 were approximately $191 thousand. Our research and development expenses during the nine months ended September 30, 2017, were approximately $263 thousand, comprised of approximately $47 thousand of ongoing research and development expenses, and additional sum of approximately $216 thousand in stock based compensation to the Company’s research and development employees.

Our marketing, general and administrative expenses during the nine months ended September 30, 2018, were approximately $1.5 million, comprised of approximately $1.5 million in payroll and service providers’ consultancy, and additional sum of $28 thousand in stock based compensation to our management, consultants and service providers. Our marketing, general and administrative expenses during the nine months ended September 30, 2017 were approximately $2.1 million, comprised of approximately $1 million in payroll and service providers’ consultancy, and an additional sum of approximately $1.1 million in stock based compensation to our management, consultants and service providers.

During the nine months ended September 30, 2018, we incurred a net loss of approximately $1.5 million. Excluding a sum of $28 thousand in stock based compensation, we incurred a net loss of approximately $656 thousand during the three month period ended September 30, 2018. During the nine months ended September 30, 2017, we incurred a net loss of approximately $2.5 million. Excluding a sum of approximately $1.2 million in stock based compensation, we incurred a net loss of $383 thousand during the three month period ended September 30, 2017.

Results of Operations during the three months ended September 30, 2018 as compared to the three months ended September 30, 2017

During the three months ended September 30, 2018, we generated approximately $90 thousand in revenues, compared to no revenues in the three months ended September 30, 2017.Our revenues are derived from the launch of Novokid® in the Netherlands and in Israel.

Our research and development expenses during the three months ended September 30, 2018 were approximately $143 thousand. Our research and development expenses during the three months ended September 30, 2017, were approximately $83 thousand, all expenses resulted from ongoing research and development expenses.

Our marketing, general and administrative expenses during the three months ended September 30, 2018, were approximately $523 thousand, comprised of approximately $514 thousand in payroll and service providers’ consultancy, and additional sum of approximately $9 thousand in stock based compensation to our management, consultants and service providers. Our marketing, general and administrative expenses during the three months ended September 30, 2017 were approximately $399 thousand, all expenses resulted from payroll and service providers’ consultancy.

During the three months ended September 30, 2018, we incurred a net loss of approximately $656 thousand. Excluding a sum of approximately $9 thousand in stock based compensation, we incurred a net loss of approximately $647 thousand during the three month period ended September 30, 2018. During the three months ended September 30, 2017, we incurred a net loss of $383 thousand.

Liquidity and Capital Resources

Our balance sheet as of September 30, 2018, reflects total assets of approximately $1.1 million, consisting mainly of cash and cash equivalents in the amount of approximately $384 thousand, accounts receivables of approximately $174 thousand, inventory of approximately $156 thousand and other receivables of approximately $244 thousand. As of December 31, 2017, our balance sheet reflects total assets of approximately $862 thousand, consisting mainly of cash and cash equivalents in the amount of approximately $590 thousand, other receivables of approximately $106 thousand, inventory of approximately $41 thousand and property and equipment, net of approximately $96 thousand.

As of September 30, 2018, we had total current liabilities of approximately $444 thousand, consisting mainly of accounts payable and accrued expenses of approximately $252 thousand, refund liability of approximately $107 thousand and note payable of approximately $85 thousand. As of December 31, 2017, we had total current liabilities of approximately $328 thousand, consisting mainly of accounts payable and accrued expenses of approximately $106 thousand, note payable of approximately $89 thousand and option liability of approximately $132 thousand.

As of September 30, 2018, we had positive working capital of approximately $514 thousand, compared to positive working capital of approximately $412 thousand at December 31, 2017. The working capital has been sufficient to sustain our operations to date, although there is substantial doubt about our ability to continue as going concern. Our total liabilities as of September 30, 2018 were approximately $473 thousand, compared to approximately $351 thousand at December 31, 2017.

During the nine months ended September 30, 2018, we used approximately $1.8 million of cash in our operating activities. This resulted mainly from an overall net loss of approximately $1.5 million, an increase in other receivables of approximately $310 thousand, an increase in inventory of approximately $121 thousand and fair value option income of approximately $132 thousand, offset by an increase in accounts payable and accrued expenses of approximately $151 thousand.

During the nine months ended September 30, 2018, our financing activities provided us with approximately $1.6 million, as compared to approximately $878 thousand in the same period in the prior year, through the issuance of common stock and proceeds from stock to be issued.

While management believes the Company will be successful in its current and planned operating activities, there can be no assurance that the Company will be successful in the achievement of sales of its products that will generate sufficient revenues to earn a profit and sustain the operations of the Company. Our ability to create sufficient working capital to sustain us over the next twelve-month period and beyond, is dependent on our ability to raise additional funds through the issuance of equity or debt instrument. There can be no assurance that sufficient capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

Going Concern Consideration

As result of the above, there is substantial doubt about our ability to continue as a going concern. Our financial statements contain additional note disclosures with respect to this matter, but no accounting adjustments that relate to this matter.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Critical Accounting Policies

There was no change to our critical accounting policies since the year ended December 31, 2017, except for the adoption of the new revenue accounting standard and the improvements to Non-Employee Share-Based Payment Accounting.

Effective January 1, 2018, the Company adopted the new accounting standard related to the recognition of revenue in contracts with customers. Since the Company had no revenues prior to January 1, 2018 the new standard had no impact to revenues and results of operations for prior periods.

The Company derives revenues from sales of its products directly or indirectly through its distributors.

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer.
	●	Identification of the performance obligations in the contract.
	●	Determination of the transaction price.
	●	Allocation of the transaction price to the performance obligations in the contract.
	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

Revenue is measured as the amount of consideration expected to receive in exchange for transferring goods to the end customer or to the distributor.

The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.

Effective July 2018, the Company early adopted the new improvement to Nonemployee Share-Based Payment Accounting with no impact on its consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer (CEO) (who is the Company’s principal executive officer) and the Company’s Chief Financial Officer (CFO) (who is the Company’s principal financial officer) to allow for timely decisions regarding required disclosure. In designing and evaluating the Company’s disclosure controls and procedures, the Company’s management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company’s management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2018, our Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

Management’s Remediation Plan

Since the time our material weaknesses were identified in early 2017 related to (i) inadequate segregation of duties consistent with control objectives; and (ii) ineffective controls over period-end financial reporting and disclosure processes we initiated the following procedures during the year ended December 31, 2017:

	(i)	Due to inadequate finance resources as of the end of Q1 2017, we hired during the second quarter of 2017 a new outsourced finance team and replaced our Chief Financial Officer.

	(ii)	Began implementing processes and controls to properly perform an effective period-end financial reporting process.

We have started to implement the following additional steps: (i) Appoint additional qualified personnel (such as a new Chief Executive Officer as of July 2018 and a new internal Chief Financial Officer as of September 2018) to address inadequate segregation of duties and ineffective controls over period-end financial reporting as well as continue implementing modifications to our operating procedures and financial controls to address such inadequacies; and (ii) Adopt sufficient policies and procedures for period-end financial reporting.

The remediation efforts, which are not completed as of September 30, 2018, set out is largely dependent upon our Company securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2018, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against our Company, nor of any proceedings that a governmental authority is contemplating against us. We know of no material proceedings to which any of our directors, officers, affiliates, owner of record or beneficially of more than 5 percent of our voting securities or security holders is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEED

On June 18, 2018, the Company entered into a subscription agreement with an investor, pursuant to which the Company issued 108,527 shares of common stock at a purchase price of $0.387 and warrants to purchase up to 70,000 shares of common stock with an exercise price of $0.60, exercisable until June 17, 2019, for a total consideration of $42,000.

On June 28, 2018, the Company entered into a subscription agreement with an investor, pursuant to which the Company issued 645,995 shares of its common stock at a purchase price of $0.387 and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until June 27, 2019, for a total consideration of $250,000.

On August 8, 2018, the Company entered into subscription agreements with several investors, pursuant to which the Company issued 1,033,592 shares of its common stock at a purchase price of $0.387 and warrants to purchase up to 666,667 stock with an exercise price of $0.60, exercisable until August 7, 2019 for a total consideration of $400,000.

On August 22, 2018 the Company entered into subscription agreements with several investors, pursuant to which the Company will issue 155,038 shares of its common stock at a purchase price of $0.387 and warrants to purchase up to 100,000 stock with an exercise price of $0.60, exercisable until August 21, 2019 for a total consideration of $60,000.

On October 28, 2018, the Company entered into an amendment to a subscription agreement entered between the Company and an investor on August 8, 2018 (the “Amendment”). Pursuant to the Amendment, the investor has increased its initial investment by an additional sum of $250,000 to a total investment of $500,000 and was issued a total of 1,915,708 shares of common stock at a price per share of $0.261, out of which 645,995 shares of common stock were issued in August 2018. In addition, the investor was issued additional warrants to purchase up to 416,667 shares of common stock with an exercise price of $0.6, exercisable until October 27, 2019.

The shares issued pursuant to the aforementioned subscription agreements have been offered pursuant to Regulation D or Regulation S under the United States Securities Act of 1933, as amended, or the Securities Act, and therefore will be restricted securities and may be offered and resold only in transactions that are exempt from registration under the Securities Act and other applicable securities laws.

With respect to grants of share options, we claimed exemption from registration under the Securities Act for these issuances under Section 4(a)(2), Regulation S promulgated under the Securities Act or Rule 701 of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE.

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.		Description

10.1		Form of Service Agreement by and between the Company and Mr. Doron Biran (incorporated herein by reference to Exhibit 10.1 on Form 8-K filed with the SEC on July 20, 2018)
10.2		Form of Employment Agreement by and between the Company and Mr. Nir Shemesh
10.3		Subscription Agreement between the Registrant and Traistman Radziejewski Fundacja Ltd., dated August 8, 2018
10.4		Subscription Agreement between the Registrant and Y.M.Y Industry Ltd., dated August 8, 2018
10.5		Amended Subscription Agreement between the Registrant and Y.M.Y Industry Ltd., dated October 28, 2018
31.1		Section 302 Certification of the Sarbanes-Oxley Act of 2002 of Doron Biran
31.2		Section 302 Certification of the Sarbanes-Oxley Act of 2002 of Nir Shemesh
32.1		Section 906 of the Sarbanes-Oxley Act of 2002 of Doron Biran
32.2		Section 906 of the Sarbanes-Oxley Act of 2002 of Nir Shemesh
101		Financial information from TechCare Corp’s Quarterly Report on Form 10-Q for the nine and three months ended September 30, 2018 formatted in XBRL (eXtensible Business Reporting Language).

* English Transition of Hebrew original document.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

	TechCare Corp.

	By:	/s/ Doron Biran
		Doron Biran
		Chief Executive Officer
		(Principal Executive Officer)

	Date:	November 13, 2018

	By:	/s/ Nir Shemesh
		Nir Shemesh
		Chief Financial Officer
		(Principal Financial and Principal Accounting Officer)

	Date:	November 13, 2018

EX-10.2 2 ex10-2.htm

EMPLOYMENT AGREEMENT

Executed on September 9, 2018

This Employment Agreement (the “Agreement”) is entered into by and between Novomic Ltd., with offices at 23 Hamelacha St., Rosh Hain, Israel (the “Company”) and Nir Shemesh, I.D. No. 021612759, of ________________________, email: nir.shemesh@gmail.com (the “Employee”).

EMPLOYMENT AND COMPENSATION

1.	The Company has agreed to employ Employee for an indefinite period and Employee has agreed to become so employed, on the terms and conditions set forth herein. The commencement date of the employment, Employee’s position, the reporting duties and other work-related terms, including salary, entitlements and fringe benefits, are specified in *Appendix A* attached hereto.

2.	Employee undertakes to devote Employee’s full time, attention, skill, and effort exclusively to the performance of Employee’s duties and undertakes not to engage, whether as an employee or otherwise, in any business, commercial or professional activities, whether or not for compensation, during Employee’s employment, without the prior written consent of the Company. Nothing contained herein shall derogate from Employee’s undertakings in *Appendix B* attached hereto.

3.	This Agreement may be terminated by either party at any time by giving the other party hereto a prior notice of such termination, as specified in Appendix A (the “Notice Period”).

4.	Notwithstanding anything to the contrary in Section 3 above, the Company may terminate the employee’s employment for Cause. In any event of termination for Cause, the Employment under this Agreement shall forthwith terminate and thereafter the Company shall not have any further liability or obligation towards Employee, including with respect to Notice Period. The term “Cause” means: (i) breach of Employee’s fiduciary duties, misappropriation of the Company’s property or any breach of Employee’s undertakings under Appendix B; or (ii) a material breach by the Employee of this Agreement, provided however, that Employee has not cured such breach (if remediable) within 7 days following a notice sent to Employee by the Company; or (iii) Employee’s indictment for a criminal offense (other than an offense for which a fine or non-custodial penalty is imposed) or involvement in sexual harassment of another employee or third party in connection with Employee’s employment; or (iv) any other circumstances under which prior notice may be denied from Employee upon termination of employment under any applicable law.

5.	Employee shall have no lien on any of the Company’s assets, equipment or any other material in Employee’s possession. Employee shall return to the Company all Company’s equipment no later than the day of termination of employer-employee relationship, prior to any unpaid leave or within 7 days following Company’s demand.

6.	Nothing herein shall derogate from any right Employee may have, in accordance with any law, expansion order, collective bargaining agreement, employment agreement or any other agreement with respect to the terms of Employee’s employment, which cannot be stipulated against.

NON DISCLOSURE, COMPETITIVE ACTIVITY AND OWNERSHIP OF INVENTIONS

7.	Simultaneously with the signing of this Agreement, Employee shall sign the Non-Disclosure, Unfair Competition and Ownership of Inventions Undertaking in favor of the Company, attached hereto as *Appendix B*.

EMPLOYEE’S REPRESENTATIONS AND UNDERTAKINGS

Employee represents, warrants, and undertakes all of the following:

8.	Employee has the ability, knowledge and qualifications needed to perform Employee’s obligations under this Agreement. Employee does not suffer from any physical or mental health issues which may have an unreasonable influence on the performance of Employee’s undertakings under this Agreement.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-2-

9.	There are no other undertakings or agreements preventing, restricting or limiting the fulfillment of Employee’s obligations under this Agreement. Employee shall not, by entering into this Agreement and performing Employee’s obligations hereunder, be deemed to be: (i) violating any right of Employee’s former employer(s), or (ii) in breach of or in conflict with, any of Employee’s obligations towards Employee’s former employer(s) or under any agreement or obligation to which Employee is bound.

10.	Employee shall inform the Company of any matter in which Employee or Employee’s immediate family has a personal interest and which might give rise to a conflict of interest with Employee’s duties under the terms of Employee’s employment, immediately upon becoming aware of such matter.

11.	Employee shall not receive any benefit from any third party, directly or indirectly in connection with Employee’s employment. In the event Employee breaches this undertaking, without derogating from any of the Company’s rights, such benefit or its value shall become the sole property of the Company and the Company may deduct the value of such benefit from any payment Employee may be entitled to. This section does not apply to gifts or benefits with insignificant value.

12.	In carrying out Employee’s duties, Employee shall not act in a way which contradicts the signature rights of the Company.

13.	Employee acknowledges and agrees that from time to time Employee may be required by the Company to travel and stay abroad as part of Employee’s obligations under this Agreement. Employee hereby acknowledges and agrees that while Employee is abroad as part of Employee’s obligations under this Agreement, Employee shall serve as a senior representative of the Company, a position which requires a special degree of personal trust, as defined in the Working Hours and Rest Law, 1951 (the “Working Hours and Rest Law”). Therefore, in these special circumstances, the provisions of the Working Hours and Rest Law shall not apply to the Employee’s employment under this Agreement. Employee acknowledges that while Employee is abroad as part of Employee’s obligations under this Agreement, Employee shall be required to work “overtime” hours, including during late hours and during “weekly hours of rest”, and that Employee shall not be granted any additional compensation with regard to such “overtime” hours. Employee acknowledges that the monetary implications of this provision have been taken into account by the parties to this Agreement in their decision on the compensation specified in Appendix A and by the Employee in the Employee’s decision to engage in this Agreement.

14.	Employee acknowledges that in extraordinary circumstances the Company may require the Employee to participate in a polygraph test. Employee agrees that: (a) the Company may rely on the results of such polygraph test; and (b) the results of such test may be presented in any legal proceedings and may be considered as valid evidence.

15.	Unless otherwise provided under this Agreement or Company’s procedures, Employee will use the Company’s equipment for the purpose of Employee’s employment only. Thus, Employee shall not use the Company’s computers/laptops and email system (including by smartphone) for personal purposes (the “Company’s Computers”), shall not store any private material on Company’s Computers and shall not store company documents on Employee’s cloud storage accounts. For personal purposes, Employee shall be entitled to use external email services (such as Gmail, Yahoo Mail, etc.).

16.	Employee acknowledges and agrees as follows: (i) the Company shall have the right to allow other employees and other third parties to use the Company’s Computers; (ii) the Company shall have the right to conduct inspections on any and all of the Company’s Computers, including inspections of email transmissions, internet usage and inspections of their content and shall have the right to use the findings of such inspections for the Company’s purposes; (iii) in light of Employee’s undertaking that the sole use of the Company’s Computers shall be for business purposes, Employee has no right to privacy in any of the Company’s Computers.

17.	Employee acknowledges and agrees that information related to the Employee and the Employee’s terms of employment at the Company, as shall be received and held by the Company (the “Information”), may be transferred to third parties, including those located abroad, subject to: (a) that such transfer shall be made only in order for the Company to comply with any relevant legal requirements or due to business purposes of the Company (including transactions related with the Company); (b) that the transferred Information shall be limited to the reasonable and necessary scope; and (c) that the receiver of the Information shall undertake, to the extent possible, to preserve the privacy of the Information, at least at the level of privacy kept by the Company itself regarding the Information.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-3-

18.	In the event this Agreement is terminated for any reason whatsoever, Employee shall cooperate with the Company and exercise Employee’s best efforts to assist in the integration of the person or persons who will assume Employee’s responsibilities into the Company.

GENERAL PROVISIONS

19.	This Agreement and all Appendices attached hereto constitute the entire agreement between the parties and supersede all prior agreements, proposals, understandings and arrangements, if any, whether oral or written, between the parties hereto with respect to the subject matter hereof. This Agreement may be amended, supplemented or modified only by a written instrument duly signed by or on behalf of each party hereto.

20.	This Agreement shall be governed by and construed in accordance with the laws of the State of Israel, without giving effect to its laws pertaining to conflict of laws. Any and all disputes in connection with this Agreement shall be submitted to the exclusive jurisdiction of the competent courts or tribunals, as relevant, located in the city of Tel-Aviv-Jaffa, Israel.

21.	Any notice or other communication in connection with this Agreement must be in writing to the address set forth in the preamble to this Agreement (or to such other address as shall be specified by like notice), sent via registered mail, messenger or email. Such notice shall be deemed given after four (4) business days, if sent via registered mail; after one (1) day if sent by messenger, provided a proof of delivery has been received; after one (1) day if sent by email, provided however, that a computerized automatic “received” approval (delivery receipt) was sent by the email server.

Employee acknowledges that:

(1)	she has read and fully understood all the provisions of this Agreement and its appendices;

(2)	she was given the opportunity to consult with third parties, including her attorneys; and

(3)	This Agreement was signed at Employee’s own free will.

Novomic Ltd.		Employee - Nir Shemesh

By:	/s/ Doron Biran	/s/ Nir Shemesh
Name:	Doron Biran
Title:	CEO

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-4-

APPENDIX A

TERMS OF EMPLOYMENT AND COMPENSATION

1.	Commencement Date, Position and Reporting - Employee’s employment shall commence on September 9, 2018, in the position of Chief Financial Officer. Employee shall report directly to Company’s Chief Executive Officer.

2.	Working Hours - Employee shall be employed on a 5-day workweek basis. Employee’s working hours shall be in accordance with the Company’s policy, as in effect from time to time. On the date of signature of this Agreement the normal working hours of the Company are 9:00 to 18:00. The Company may instruct the Employee to work overtime. Employee’s entitlement to breaks will be in accordance with any applicable law. Employee’s rest day shall be Saturday.

3.	Notice Period - During the first 6 months of Employee’s employment, the Notice Period shall be in accordance with the Prior Notice for Dismissal and Resignation Law, 2001; Thereafter - the Notice Period shall be 1 month. Notwithstanding the above, the Company shall be entitled to consider the Employee’s clear and unequivocal oral notice of resignation as binding, in the absence of written notice.

4.	Salary – A gross monthly salary of NIS 17,500 (the “Base Salary”). An additional global payment of NIS 4,700 per month for up to 40 overtime hours at an hourly rate of 125% and NIS 2,800 per month for up to 20 overtime hours at an hourly rate of 150% (the “Global Overtime Payment”) – up to 60 overtime hours in total (the “Quota”). Employee will be entitled to full Global Overtime Payment even if the entire Quota was not met.

The parties estimate that the Quota reflects the actual overtime hours that Employee may work and therefore, the Global Overtime Payment is sufficient to cover all overtime work. The Company undertakes that the Global Overtime Payment shall be raised together with any Base Salary increase.

Upon the first anniversary of the Employee’s employment by the Company, his Salary shall be increased by 5%.

The parties agree that the Global Overtime Payment be treated, for all intents and purposes, as salary payment and therefore the Base Salary and the Global Overtime Payment shall be collectively referred to as the “Salary”. Any payment or benefit under this Appendix A, other than the Salary, shall not be considered as a salary for any purpose whatsoever, and the Employee shall not maintain or claim otherwise. The Salary shall be payable on such dates as required by law.

6.	Pension Arrangements - The Company shall insure the Employee under an accepted ‘Managers’ Insurance’ plan (the “Managers’ Insurance Policy”), a Pension Fund (the “Pension Fund”) or a combination of both, at Employee’s choice, according to the following rates and conditions:

6.1.	Managers’ Insurance Policy:

	6.1.1.	Disability Insurance - The Company, at its own discretion and expense, shall purchase a disability insurance, under normal and acceptable conditions, which would insure 75% of the Salary (the “Disability Insurance”). The Company’s contribution for Disability Insurance shall, in no circumstances, exceed the amount of 2½% of the Salary.

	6.1.2.	Severance - an amount equal to 8⅓% of the Salary;

	6.1.3.	Company’s contribution towards pension - the difference between 6.5% of the Salary and the actual percentage of the Salary contributed towards Disability Insurance, provided that the Company’s contribution towards pension shall not be lesser than 5% of the Salary.

	6.1.4.	Employee’s contribution towards pension – 6% of the Salary.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-5-

6.2.

Pension Fund: Severance - an amount equal to 8⅓% of the Salary; Pension - an amount equal to 6.5% of the Salary. In addition, the Company will deduct from Employee’s monthly paycheck a sum equal to 6% of the Salary as Employee’s contribution.

7.	Study Fund. The Company and the Employee shall contribute to a study fund pursuant to applicable law.

8.	Pension Funds Release - The Company and Employee agree to adopt the provisions of the “General Approval of the Minister of Labor and Social Welfare Regarding Payments by Employers to a Pension Fund and Insurance Fund in lieu of Severance Pay”, which was issued in accordance with the Severance Pay Law, 1963 (the “General Acknowledgement”), as amended from time to time. The General Acknowledgment is attached to this Agreement as *Appendix C*. The Company waives any right that it may have for the repayment of any monies paid by it to the Managers’ Insurance Policy and/or the Pension Fund, unless the right of Employee to severance has been revoked by a judicial decision, under Section 16 or 17 of the Severance Pay Law, 1963 (to the extent of such revocation) or in case Employee withdrew monies from the Pension Fund or the Insurance Fund for any reason other than death, disability or retirement at the age of sixty or thereafter.

Employee hereby acknowledges and confirms that the Company’s contributions towards the Employee’s Insurance Policy and/or the Pension Fund are and shall be in lieu of severance pay, if Employee shall be entitled to such, according to Section 14 of the Severance Pay Law, 1963 and in accordance with the General Acknowledgement.

9.	Vacation - Employee shall be entitled to 20 vacation days (the “Vacation Days”) with respect to each full year of continuous employment with the Company. Employee shall be entitled to carry forward the unused Vacation Days in accordance with the terms set out in the Leave Law. Any contractual vacation days (annual leave days granted in excess of the amount required by law or by any applicable expansion order) remaining unused at the end of any 12-month period of employment, shall be forfeited with no compensation payable.

10.	Sick Leave - Employee shall be entitled to sick leave in accordance with the provisions of the Sick Pay Law, 1976. In the event Employee is absent from work due to illness, Employee shall notify the Company of the illness on the first day of absence, unless Employee is unable to provide such notice due to Employee’s medical condition, in which case the notice will be delivered as soon as possible. Such notice shall include, inter alia, the estimated period in which Employee will be absent from work. Employee shall be reimbursed for his sick leave commencing on his first day of leave.

11.	Recuperation Pay - Employee shall be entitled to Recuperation Pay (“Dmey Havra’a”) in accordance with the applicable expansion order.

12.	Car

The Company shall lease a Hyundai i25 (the “Car”) for the Employee and shall bear the costs of the Car, including rental fees, registration and gasoline. The Car shall be used by the Employee pursuant to and in accordance with the Company’s policy and guidelines from time to time.

13.	Business Expenses - The Company shall reimburse Employee for necessary and customary business expenses incurred by Employee, in accordance with the Company’s policy, as amended from time to time.

14.	Stock Options – The Employee shall be entitled to receive such stock options, representing 1% of the issued share capital of the Company’s parent company, TechCare Corp. to vest in annual increments over 4 years of continuous employment by the Company (the “Options”). The exercise price of the Options shall be equivalent to the average VWAP of the stock during a 30 days’ period prior to the signing of this Agreement. The grant of the Options shall be subject to the approval of the Company’s Board of Directors and pursuant a stock award agreement.

15.	Annual Bonus. In the event shall generate an annual operational profit of $1,000,000, the Employee shall be entitled to a bonus equivalent to 2 monthly Base Salaries.

16.	Taxes - The Company shall withhold, deduct, transfer and/or charge Employee with all taxes and other compulsory payments as required under law in respect of, or resulting from, the compensation paid to or received by Employee and in respect of all the benefits that Employee is or may be entitled to.

Novomic Ltd.		Employee – Nir Shemesh

By:	/s/ Doron Biran	/s/ Nir Shemesh
Name:	Doron Biran
Title:	CEO

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-6-

APPENDIX B

THIS UNDERTAKING (“Undertaking”) is entered into as of September 9, 2018, by Nir Shemesh, I.D. No. 021612759, of __________________________, email: Nir.Shemesh@gmail.com (the “Employee”).

WHEREAS, Employee wishes to be employed by Novomic Ltd. (the “Company”); and

WHEREAS, it is critical for the Company to preserve and protect its Confidential Information (as defined below) and its rights in Inventions (as defined below) and in all related intellectual property, and Employee is entering into this Undertaking as a condition to Employee’s employment with the Company.

NOW, THEREFORE, the Employee undertakes and warrants towards the Company as follows:

References herein to the term “Company” shall include any of the Company’s direct or indirect parent, subsidiary and affiliated companies, and their respective successors and assigns.

1.	Confidentiality.

1.1.	Employee acknowledges that Employee may have access to information that relates to the Company, its business, assets, financial condition, affairs, activities, plans and projections, customers, suppliers, partners, and other third parties with whom the Company agreed or agrees, from time to time, to hold information of such party in confidence (the “Confidential Information”). Confidential Information shall include, without limitation, information, whether or not marked or designated as confidential, concerning technology, products, research and development, patents, copyrights, inventions, trade secrets, test results, formulae, processes, data, know-how, marketing, promotion, business and financial plans, policies, practices, strategies, surveys, analyses and forecasts, financial information, customer lists, agreements, transactions, undertakings and data concerning employees, consultants, officers, directors, and shareholders. Confidential Information includes information in any form or media, whether documentary, written, oral, magnetic, electronically transmitted, through presentation or demonstration or computer generated. Confidential Information shall not include information that: (i) has become part of the public domain not as a result of a breach of any obligation owed by Employee to the Company; or (ii) is required to be disclosed by law or the binding rules of any governmental organization, provided, however, that Employee gives the Company prompt notice thereof so that the Company may seek a protective order or other appropriate remedy, and further provided, that in the event that such protective order or other remedy is not obtained, Employee shall furnish only that portion of the Confidential Information which is legally required, and shall exercise all reasonable efforts required to obtain confidential treatment for such information.

1.2.	Employee acknowledges and understands that the employment by the Company and the access to Confidential Information creates a relationship of confidence and trust with respect to such Confidential Information.

1.3.	During the term of Employee’s employment and at any time after termination or expiration thereof, for any reason, Employee shall keep in strict confidence and trust, shall safeguard, and shall not disclose to any person or entity, nor use for the benefit of any party other than the Company, any Confidential Information, other than with the prior express consent of the Company.

1.4.	All right, title and interest in and to Confidential Information are and shall remain the sole and exclusive property of the Company or of the third party providing such Confidential Information to the Company, as the case may be. Without limitation of the foregoing, Employee agrees and acknowledges that all memoranda, books, notes, records, email transmissions, charts, formulae, specifications, lists and other documents (contained on any media whatsoever) made, reproduced, compiled, received, held or used by Employee in connection with the employment by the Company or that otherwise relates to any Confidential Information (the “Confidential Material”), shall be the Company’s sole and exclusive property and shall be deemed to be Confidential Information. All originals, copies, reproductions and summaries of the Confidential Materials shall be delivered by Employee to the Company upon termination or expiration of Employee’s employment for any reason, or at any earlier time at the request of the Company, without Employee retaining any copies thereof.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-7-

1.5.	During the term of Employee’s employment with the Company, Employee shall not remove from the Company’s offices or premises any Confidential Material unless and to the extent necessary in connection with the duties and responsibilities of Employee and permitted pursuant to the then applicable policies and regulations of the Company. In the event that such Confidential Material is duly removed from the Company’s offices or premises, Employee shall take all actions necessary in order to secure the safekeeping and confidentiality of such Confidential Material and return the Confidential Material to their proper files or location as promptly as possible after such use.

1.6.	During the term of Employee’s employment with the Company, Employee will not improperly use or disclose any proprietary or confidential information or trade secrets, and will not bring onto the premises of the Company any unpublished documents or any property, belonging to any former employer or any other person to whom Employee has an obligation of confidentiality and/or non-use (including, without limitation, any academic institution or any entity related thereto), unless generally available to the public or consented to in writing by that person.

2.	Unfair Competition and Solicitation.

2.1.	Employee undertakes that during the term of employment with the Company Employee shall not engage, establish, open or in any manner whatsoever become involved, directly or indirectly, either as an employee, owner, partner, agent, shareholder, director, consultant or otherwise, in any business, occupation, work or any other activity which competes with the business of the Company.

2.2.	Employee undertakes that for a period of twelve (12) months following termination of Employee’s employment for whatever reason Employee shall not engage, establish, open or in any manner whatsoever become involved, directly or indirectly, either as an employee, owner, partner, agent, shareholder, director, consultant or otherwise, in any business, occupation, work or any other activity which is reasonably likely to involve or require the use of any of the Company’s Major Assets, as defined below. Employee confirms that engagement, establishment, opening or involvement, directly or indirectly, either as an employee, owner, partner, agent, shareholder, director, consultant or otherwise, in any business, occupation, work or any other activity which competes with the business of the Company as conducted during the term of employment or contemplated, during such term, to be conducted, is likely to require the use of all or a portion of the Company’s Major Assets.

2.3.	Employee hereby declares that he/she is aware that a portion of the Salary contains additional consideration in exchange for the Employee fully undertaking the non-compete provisions in Sections 2.1 and 2.2 above. Notwithstanding anything in this provision, the Employee declares that he/she is financially capable of undertaking these non-compete provisions.

2.4.	Employee undertakes that during the term of employment with the Company and for a period of twelve (12) months thereafter: (i) Employee shall not, directly or indirectly, solicit, hire or retain as an employee, consultant or otherwise, any employee of the Company or induce or attempt to induce any such employee to terminate or reduce the scope of such employee’s employment with the Company; and (ii) Employee shall not, directly or indirectly, solicit or induce, or attempt to solicit or induce, any consultant, service provider, agent, distributor, customer or supplier of the Company to terminate, reduce or modify the scope of such person’s engagement with the Company.

2.5.	Employee acknowledges that in light of Employee’s position with the Company and in view of Employee’s exposure to, and involvement in, the Company’s sensitive and valuable proprietary information, property (including, intellectual property) and technologies, as well as its goodwill and business plans (the “Company’s Major Assets”), the provisions of this Section 2 above are reasonable and necessary to legitimately protect the Company’s Major Assets, and are’s Major Assets, and are being undertaken by Employee as a condition to the employment of Employee by the Company. Employee confirms that Employee has carefully reviewed the provisions of this Section 2, fully understands the consequences thereof and has assessed the respective advantages and disadvantages to Employee of entering into this Undertaking and, specifically, Section 2 hereof.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-8-

3.	Ownership of Inventions.

3.1.	Employee will notify and disclose in writing to the Company, or any persons designated by the Company from time to time, all information, improvements, inventions, trademarks, works, designs, trade secrets, formulae, processes, techniques, know-how and data, whether or not patentable or registerable under copyright or any similar laws, made or conceived or reduced to practice or learned by Employee, either alone or jointly with others, during Employee’s employment with the Company (including after hours, on weekends or during vacation time) (all such information, improvements, inventions, trademarks, works, designs, trade secrets, formulae, processes, techniques, know-how, and data are hereinafter referred to as the “Invention(s)”) immediately upon discovery, receipt or invention as applicable.

3.2.	Employee agrees that all the Inventions are, upon creation, Inventions of the Company, shall be the sole property of the Company and its assignees, and the Company and its assignees shall be the sole owner of all title, rights and interest in and to any patents, copyrights, trade secrets and all other rights of any kind or nature, including moral rights, in connection with such Inventions. Employee hereby irrevocably and unconditionally assigns to the Company all the following with respect to any and all Inventions: (i) all title, rights and interest in and to any patents, patent applications, and patent rights, including any and all continuations or extensions thereof; (ii) rights associated with works of authorship, including copyrights and copyright applications, Moral Rights (as defined below) and mask work rights; (iii) rights relating to the protection of trade secrets and confidential information; (iv) design rights and industrial property rights; (v) any other proprietary rights relating to intangible property including trademarks, service marks and applications thereof, trade names and packaging and all goodwill associated with the same; (vi) any and all title, rights and interest in and to any Invention; and (vii) all rights to sue for any infringement of any of the foregoing rights and the right to all income, royalties, damages and payments with respect to any of the foregoing rights. Employee also hereby forever waives and agrees never to assert any and all Moral Rights Employee may have in or with respect to any Inventions, even after termination of employment on behalf of the Company. “Moral Rights” means any right to claim authorship of a work, any right to object to any distortion or other modification of a work, and any similar right, existing under the law of any country in the world, or under any treaty.

3.3.	Employee has attached hereto, as Exhibit B-1, a list describing all information, improvements, inventions, formulae, processes, techniques, know-how and data, whether or not patentable or registerable under copyright or any similar laws, and whether or not reduced to practice, original works of authorship and trade secrets made or conceived by or belonging to the Employee (whether made solely by the Employee or jointly with others) that: (i) were developed by the Employee prior to the Employee’s engagement with the Company (collectively, the “Prior Inventions”), (ii) relate to the Company’s actual or proposed business, products or research and development, and (iii) are not assigned to the Company hereunder; or, if Exhibit B-1 is incomplete or if no such list is attached, the Employee represents that there are no such Prior Inventions.

3.4.	Employee further agrees to perform, during and after employment, all acts deemed reasonably necessary or desirable by the Company to permit and assist it, at the Company’s expense, in obtaining, maintaining, defending and enforcing the Inventions in any and all countries. Such acts may include, but are not limited to, execution of documents and assistance or cooperation in legal proceedings. Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents, as Employee’s agents and attorneys-in-fact to act for and on Employee’s behalf and instead of Employee, to execute and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and effect as if executed by Employee.

3.5.	Employee shall not be entitled to any monetary consideration or any other consideration except as explicitly set forth in the employment agreement between Employee and the Company. Without limitation of the foregoing, Employee irrevocably confirms that the consideration explicitly set forth in the employment agreement is in lieu of any rights for compensation that may arise in connection with the Inventions under applicable law and waives any right to claim royalties or other consideration with respect to any Invention, including under Section 134 of the Israeli Patent Law - 1967. Any oral understanding, communication or agreement with respect to the matters set forth herein, not memorialized in writing and duly signed by the Company, shall be void.

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-9-

4.	General.

4.1.	Employee represents that the performance of all the terms of this Undertaking and Employee’s duties as an employee of the Company does not and will not breach any invention assignment, proprietary information, non-compete, confidentiality or similar agreements with, or rules, regulations or policies of, any former employer or other party (including, without limitation, any academic institution or any entity related thereto). Employee acknowledges that the Company is relying upon the truthfulness and accuracy of such representations in employing Employee.

4.2.	Employee acknowledges that the provisions of this Undertaking serve as an integral part of the terms of Employee’s employment and reflect the reasonable requirements of the Company in order to protect its legitimate interests with respect to the subject matter hereof.

4.3.	Employee recognizes and acknowledges that in the event of a breach or threatened breach of this Undertaking by Employee, the Company may suffer irreparable harm or damage and will, therefore, be entitled to injunctive relief to enforce this Undertaking (without limitation to any other remedy at law or in equity).

4.4.	This Undertaking is governed by and construed in accordance with the laws of the State of Israel, without giving effect to its laws pertaining to conflict of laws. Any and all disputes in connection with this Undertaking shall be submitted to the exclusive jurisdiction of the competent courts or tribunals, as relevant, located in the city of Tel-Aviv-Jaffa, Israel.

4.5.	If any provision of this Undertaking is determined by any court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Undertaking only with respect to such jurisdiction in which such clause or provision cannot be enforced, and the remainder of this Undertaking shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Undertaking. In addition, if any particular provision contained in this Undertaking shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing the scope of such provision so that the provision is enforceable to the fullest extent compatible with applicable law.

4.6.	The provisions of this Undertaking shall continue and remain in full force and effect following the termination or expiration of the employment relationship between the Company and Employee, for whatever reason. This Undertaking shall not serve in any manner so as to derogate from any of Employee’s obligations and liabilities under any applicable law.

4.7.	Employee hereby consents that, following the termination or expiration of the employment relationship hereunder, the Company may notify the Employee’s new employer about the Employee’s rights and obligations under this Undertaking.

4.8.	This Undertaking constitutes the entire agreement between Employee and the Company with respect to the subject matter hereof and supersedes all prior agreements, proposals, understandings and arrangements, if any, whether oral or written, with respect to the subject matter hereof. No amendment, waiver or modification of any obligation under this Undertaking will be enforceable unless set forth in a writing signed by the Company. No delay or failure to require performance of any provision of this Undertaking shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Undertaking as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other than the actual performance specifically waived.

4.9.	This Undertaking, the rights of the Company hereunder, and the obligations of Employee hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. The Company may assign any of its rights under this Undertaking. Employee may not assign, whether voluntarily or by operation of law, any of its obligations under this Undertaking, except with the prior written consent of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Undertaking as of the date first mentioned above.

/S/ Nir Shemesh

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

-10-

APPENDIX C

General Approval Regarding Payments by Employers to a Pension Fund and Insurance Fund in lieu of Severance Pay

In accordance with the Severance Pay Law 5723-1963

By virtue of my authority under Section 14 of the Severance Pay Law 5723-1963 (hereinafter, the “Law”), I hereby confirm that payments made by an employer beginning on the date this authorization is publicized, for its employee, towards a comprehensive pension in a provident fund for benefit payments, which is not an insurance fund as implied in the Income Tax Regulations (Rules for Approving and Managing Provident Funds) 5724-1964 (hereinafter, a “Pension Fund”), or towards Managers’ Insurance that includes an option for benefit payments (hereinafter, an “Insurance Fund”) or a combination of payments towards a Pension Fund and an Insurance Fund (hereinafter, “Employer Payments”), shall be in lieu of the severance pay to which the said employee is entitled for the wages of which the said payments were paid and the period for which they were paid (hereinafter, the “Exempted Salary”), provided the following conditions shall be met:

1.	Employer Payments -

	(a)	To a Pension Fund are not less than 14.33% of the Exempted Salary or 12% of the Exempted Salary if the employer pays for its employee, in addition to this, supplementary severance payments towards a Severance Pay Fund or an Insurance Fund in the name of the employee, at a rate of 2.33% of the Exempted Salary. If the employer does not pay the said 2.33% in addition to the 12%, its payments shall be only in lieu of 72% of the employee’s severance pay.

	(b)	To an Insurance Fund are not less than one of the following:

		(1)	13 1/3% of the Exempted Salary, if the employer pays for its employee payments for additional monthly income support in case of employee’s inability to work, through a plan approved by the Supervisor for Capital Markets, Insurance and Savings in the Ministry of Finance, at a rate necessary to guarantee at least 75% of the Exempted Salary, or at a rate of 2 1/2% of the Exempted Salary, whichever is lower (hereinafter, “Loss of Work Capacity Insurance”).

		(2)	11% of the Exempted Salary, if the employer paid an additional Payment for the Loss of Work Capacity Insurance, and in such case the employer’s payments shall be only in lieu of 72% of the employee’s severance pay. If, in addition to such payments, the employer has also paid payments for the supplement of severance pay to a Severance Pay Fund or an Insurance Fund under the name of the employee at a rate of 2 1/3% of the Exempted Salary, the employer’s payments shall be in lieu of 100% of the employee’s severance pay.

2.	Not later than three months from the commencement of the employer’s payments a written agreement shall be prepared between the employer and the employee, which shall include:

	(a)	The employee’s agreement to an arrangement in accordance with this authorization, in wording that specifies the employer’s payments and the Pension Fund and the Insurance Fund, as relevant. The said agreement shall also include the wording of this authorization.

	(b)	The employer’s prior waiver of any right it may have to a financial reimbursement for all or part of its payments, unless the employee’s right to severance pay is rescinded by a judicial decree by virtue of Sections 16 or 17 of the Law, or that the employee withdrew funds from the Pension Fund or from the Insurance Fund not for a qualifying incident. In this regard a “qualifying incident”- death, disability or retirement at the age of 60 or older.

	(c)	This authorization shall not derogate from the employee’s right to severance pay under the Law, collective agreement, expansion order or employment contract, for wages exceeding The Exempted Salary.

	(-)

	Eliyahu Yishai

	Minister of Labor and Social Welfare

Company: /s/ Doron Biran

Employee: /s/ Nir Shemesh

EX-10.3 3 ex10-3.htm

THIS SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SHARES OF COMMON STOCK (THE “OFFERING”), IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S PROMULGATED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).

THE SHARES THAT ARE SUBJECT TO THIS SUBSCRIPTION AGREEMENT IN RELIANCE ON REGULATION S (THE “SUBSCRIPTION AGREEMENT”) HAVE NOT BEEN REGISTERED UNDER THE ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE ACT.

TECHCARE CORP.

(A Delaware corporation)

SUBSCRIPTION AGREEMENT

DATED: August 8, 2018 (the “Effective Date”)

1. The Offering

1.1 On the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, Traistman Radziejewski Fundacja Ltd. (Israeli Co. No. 514498856), of 15A Yahalom St., Shoham, Israel (C/O Oren Traistman) (the “Investor”) hereby agrees to subscribe for and purchase 258,398 shares of common stock, par value $0.0001 (the “Initial Shares”) offered by TechCare Corp., a Delaware corporation with offices located at 1140 Avenue of the Americas, New York, NY 10036 (the “Company”), at a purchase price per share of US$ 0.387 (the “Share Purchase Price”), for an aggregate consideration of US$100,000 (the “Subscription Proceeds”), all pursuant to the terms and conditions set forth in this Subscription Agreement.

1.2 In addition, on the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, the Investor shall be entitled, until the 12 month anniversary of the date hereof, to subscribe for, and purchase, 166,667 additional Shares of TechCare Corp. (the “Additional Shares” and together with the Initial Shares, the “Shares”) at a purchase price per share of US$0.60, for an aggregate consideration of US$100,000 (the “Additional Subscription Proceeds”), all pursuant to the terms and conditions set forth in this Subscription Agreement

1.3 The undersigned Investor understands that this Offering by the Company is being made only to persons/institutions who are not U.S. Persons, as defined in Rule 902 of Regulation S promulgated by the United States Securities and Exchange Commission (“SEC”) under the Securities Act of 1933, as amended (the “Act”) and that the Company will not offer Shares nor accept subscriptions from any person and/or entity that is not a U.S. Person as defined in Rule 902 of Regulation S.

1.4 On the basis of the representations and warranties of the Investor and subject to the terms and conditions set forth herein, the Company, by its execution and delivery of the counter-signed copy of this Subscription Agreement, hereby irrevocably agrees to accept the subscription and sell to the undersigned the Shares subscribed for herein.

1.5 Subject to the terms hereof, this Subscription Agreement will be effective upon receipt by the Company of the Subscription Proceeds.

1.6 Within seven (7) days of from the receipt of the Subscription Proceeds or the Additional Subscription Proceeds by the Company, as applicable, the Company shall deliver to the Investor book entry confirmation representing the number of Shares purchased by the Investor. The Shares shall be registered on the books of the Company as follows: Traistman Radziejewski Fundacja Ltd. (Israeli Co. No. 514498856), of 15A Yahalom St., Shoham, Israel (C/O Oren Traistman).

2. Payment of Subscription Proceeds and Additional Subscription Proceeds

The Investor understands that the Subscription Proceeds and Additional Subscription Proceeds, as applicable, are payable to the Company by electronic wire transfer pursuant to the Company’s wiring instructions to be provided thereto.

3. Documents/Deliveries Required from the Investor

3.1 The Investor understands and agrees that as a condition to the Company’s acceptance of this subscription, the undersigned will complete, sign and return to the Company an executed copy of this Subscription Agreement together with any and all attachments hereto.

3.2 The Investor will complete, sign and return to the Company as soon as possible, on request by the Company, any other documents, questionnaires, notices and undertakings as may be reasonably required by regulatory authorities and applicable law.

3.3 The Investor will pay/deliver the Subscription Proceeds and the Additional Subscription Proceeds, as applicable, to the Company as provided in Section 2 above subject to the Company’s execution and acceptance of this Subscription Agreement.

4. Acknowledgements of Investor

4.1 The Investor acknowledges and agrees that:

(i) the Shares being offered have not been registered under the Act, or under any state securities or “blue sky” laws of any state of the United States, and, unless so registered, the Shares may neither be offered nor sold in the United States or, directly or indirectly, to U.S. Persons, as that term is defined in Rule 902 of Regulation S under the Act, except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Act;

(ii) the Investor acknowledges that the Company has not undertaken, and will have no obligation, to register the under the Act;

(iii) the decision to execute this Subscription Agreement has not been based upon any oral or written representation as to fact or otherwise made by or on behalf of the Company, and such decision is based entirely upon a review of information (the receipt of which is hereby acknowledged) which has been filed by the Company with the SEC under the Securities Exchange Act of 1934 (collectively, the “Exchange act Reports”);

(iv) no securities commission or similar regulatory authority has reviewed or passed on the merits of an investment in the Shares;

(v) there is no government or other insurance covering any investment in the Shares;

(vi) there are risks associated with an investment in the Shares, as more fully described in certain information forming part of the Exchange Act Reports;

(vii) the Investor has had a reasonable opportunity to ask questions of and receive answers from the Company in connection with the Offering and to obtain additional information, to the extent possessed or obtainable without unreasonable effort or expense, necessary to verify the accuracy of the information about the Company;

(viii) the books and records of the Company were available upon reasonable notice for inspection, subject to certain confidentiality restrictions, by the Investor during reasonable business hours at its principal place of business, and all documents, records and books in connection with the distribution of the Shares hereunder have been made available for inspection by the Investor, the Investor’s attorney and/or advisor(s), if any;

(ix) there is no guarantee that the Shares will be listed on any stock exchange or automated dealer quotation system and no representation has been made to the Investor that the Shares will be listed on any stock exchange or automated dealer quotation system;

(x) the Shares are assignable only with the prior written consent of the Company, which consent will not be unreasonably denied, provided that any such transfer is made in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the Act or pursuant to an available exemption from the registration requirements of the Act; and

(xi) this Subscription Agreement is not enforceable by the Investor unless it has been accepted by the Company.

5. Representations, Warranties and Covenants of the Investor

5.1 The Investor hereby represents and warrants to and covenants with the Company (which representations, warranties and covenants shall be true and correct as of the date hereof and as of the subscription date of the Additional Shares, and will survive the execution and delivery of this Subscription Agreement) that:

(i) the Investor has the legal capacity and competence to enter into and execute this Subscription Agreement and to take all actions required pursuant hereto and, if the Investor is a corporation, it is duly incorporated and validly subsisting under the laws of its jurisdiction of incorporation and all necessary approvals by its directors, shareholders and others have been obtained to authorize execution and performance of this Subscription Agreement on behalf of the Investor;

(ii) entering into of this Subscription Agreement and the transactions contemplated hereby do not result in the violation of any of the terms and provisions of any law applicable to, or the corporate documents of, the Investor or of any agreement, written or oral, to which the Investor may be a party or by which the Investor is or may be bound;

(iii) the Investor has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the Investor enforceable against the Investor;

(iv) the Investor is not a U.S. Person;

(v) the Investor is not acquiring the Shares for the account or benefit of, directly or indirectly, any U.S. Person;

(vi) the Investor is resident of the jurisdiction set out under the heading “Name and Address of Investor” on the signature page of this Subscription Agreement;

(vii) the Investor is and will be outside the United States when receiving and executing this Subscription Agreement and is acquiring the Shares as principal for the Investor’s own account (except for the circumstances outlined in paragraph 5.1), for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, and no other person has a direct or indirect beneficial interest in the Shares;

(ix) the Investor is acquiring the Shares for investment only and not with a view to resale or distribution and, in particular, it has no intention to distribute either directly or indirectly any of the Shares in the United States or to U.S. Persons;

(x) the Investor is not an underwriter of, or dealer in, the Shares of the Company, nor is the Investor participating, pursuant to a contractual agreement or otherwise, in the distribution of the Shares;

(xi) the Investor:

(a) is able to fend for itself in connection with the Offering; and

(b) has such knowledge and experience in business matters as to be capable of evaluating the merits and risks of its prospective investment in the Company’s Shares offered hereby; and

(c) has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment;

(xii) if the Investor is acquiring the Shares as a fiduciary or agent for one or more investor accounts, the Investor has sole investment discretion with respect to each such account and it has full power to make the foregoing acknowledgements, representations and agreements on behalf of such account, and the investor accounts, if any, for which the Investor acts as a fiduciary or agent satisfy the definition of an “Accredited Investor”, as the term is defined in Rule 501 of Regulation D under the Act;

(xiii) the Investor acknowledges that the Investor has not acquired the Shares as a result of, and will not itself engage in, any “directed selling efforts” (as defined in Regulation S under the Act) in the United States in respect of any of the Shares which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Shares, provided, however, that the Investor may sell or otherwise dispose of any of the Shares pursuant to an effective registration statement under the Act and any applicable state securities laws or under an exemption from such registration requirements and as otherwise provided herein;

(xiv) the Investor acknowledges that:

(a) he has not received nor is he aware of any advertisement of any of the Shares;

(b) no person has made to the Investor any written or oral representations that any person will resell or repurchase any of the Shares; and

6. Conditions Precedent.

The undertaking of the Investors shall be subject to and contingent upon the following:

6.1 Prior to the Effective Date, the Company shall have secured all permits, consents and authorizations that shall be necessary or required lawfully to consummate this Subscription Agreement and to issue Shares in accordance with the terms of this Subscription Agreement. The Company has all requisite corporate power to own and operate its property and assets, to perform all its obligations under all agreements and instruments to which it is a party or by which it is bound, and to carry on the business of the Company as presently conducted and as proposed to be conducted. The Company is in compliance with all applicable laws, including all laws pertaining to it as a public company. All issued and outstanding shares of the Company have been duly authorized, and are validly issued and outstanding and fully paid and non-assessable. The Shares, when issued in accordance with this Subscription Agreement, will be duly authorized, validly issued, fully paid, non-assessable, and free of any preemptive rights, and will have the rights, preferences, privileges, and restrictions set forth in the Certificate of Incorporation of the Company, and will be issued free and clear of any liens, claims, encumbrances or third party rights of any kind and duly registered in the name of the Investor in the Company’s register of members.

6.2 The Company has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the Investor enforceable against the Investor.

6.3 The acquisition of and subscription for the Shares by the Investor as contemplated in this Subscription Agreement complies with or is exempt from the applicable securities legislation of the jurisdiction of residence of the Investor.

7. Acknowledgement and Waiver

The Investor has acknowledged that the decision to subscribe for and purchase the Shares was solely made on the basis of publicly available information contained in the Exchange Act Reports. The Investor hereby waives, to the fullest extent permitted by law, any rights of withdrawal, rescission or compensation for damages to which the Investor might be entitled in connection with the distribution of any of the Shares.

8. Restrictive Legend on Subject Securities

8.1 The Investor hereby acknowledges that upon the issuance thereof, and until such time as the same is no longer required under the applicable securities laws and regulations, certificates or book entry forms evidencing the Shares will bear a legend in substantially the following form:

THE SECURITIES REPRESENTED BY THE SHARES HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).

REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE ACT.

8.2 The Investor hereby acknowledges and agrees to the Company making a notation on its records in order to implement the restrictions on transfer set forth and described in this Subscription Agreement.

9. Costs

The Investor acknowledges and agrees that all costs and expenses incurred by the Investor (including any fees and disbursements of any counsel or other professional retained by the Investor) relating to the purchase of the Shares will be borne by the Investor.

10. Governing Law

This Subscription Agreement is governed by the laws of the State of New York. The Investor, in his personal or corporate capacity and, if applicable, on behalf of each beneficial purchaser for whom it is acting, irrevocably agrees to the jurisdiction of the courts of the State of New York.

11. Survival

This Subscription Agreement, including without limitation the representations, warranties and covenants contained herein, will survive and continue in full force and effect and be binding upon the parties hereto notwithstanding the completion of the purchase of the Shares by the Investor pursuant hereto.

12. Assignment

This Subscription Agreement is transferable or assignable only with the prior written consent of the Company, which consent will not be unreasonably denied.

13. Severability

The invalidity or unenforceability of any particular provision of this Subscription Agreement will not affect or limit the validity or enforceability of the remaining provisions of this Subscription Agreement.

14. Entire Agreement

Except as expressly provided in this Subscription Agreement and in the agreements, instruments and other documents contemplated or provided for herein, this Subscription Agreement contains the entire agreement between the parties with respect to the sale of the Shares and there are no other terms, conditions, representations or warranties, whether expressed, implied, oral or written, by statute or common law, by the Company or by anyone else.

15. Notices

All notices here under will be in writing and will be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Investor will be directed to the address on the Investor’s signature page and notices to the Company will be directed to it at the address first set forth above unless another address will be provided to the Investor by the Company in writing.

16. Counterparts and Electronic Means

This Subscription Agreement may be executed in any number of counterparts, each of which, when so executed and delivered, will constitute an original and all of which together will constitute one instrument. Delivery of an executed copy of this Subscription Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Subscription Agreement as of the date hereinafter set forth.

IN WITNESS WHEREOF the Investor has duly executed this Subscription Agreement as of the date of acceptance by the Company.

	Traistman Radziejewski Fundacja Ltd.
	(Name of Investor)

	/s/: Traistman Radziejewski Fundacja Ltd.
	(Signature of Investor)

	15A Yahalom St., Shoham, Israel (C/O Oren Traistman)
	(Address of Investor)

A C C E P T A N C E

The above-mentioned Subscription Agreement in respect of the Shares is hereby accepted by TechCare Corp.

DATED this 8^th day of August, 2018

TechCare Corp.

/s/: Tzvi Yemini
Name:	Zvi Yemini
Title:	Chairman

EX-10.4 4 ex10-4.htm

TECHCARE CORP.

(A Delaware corporation)

SUBSCRIPTION AGREEMENT

DATED: Aug 8, 2018 (the “Effective Date”)

1. The Offering

1.1 On the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, Y.M.Y Industry Ltd. (Israeli Company No. 512680539), of 38 Yefet St., Tel Aviv-Yafo, Israel (the “Investor”) hereby agrees to subscribe for and purchase 645,995 shares of common stock, par value $0.0001 (the “Initial Shares”) offered by TechCare Corp., a Delaware corporation with offices located at 1140 Avenue of the Americas, New York, NY 10036 (the “Company”), at a purchase price per share of US$ 0.387 (the “Share Purchase Price”), for an aggregate consideration of US$250,000 (the “Subscription Proceeds”), as of the date hereof, all pursuant to the terms and conditions set forth in this Subscription Agreement.

1.2 In addition, on the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, the Investor shall be entitled, but not obligated, until the twelve month anniversary of the date hereof, to subscribe for, and purchase, 416,667 additional Shares of TechCare Corp. (the “Additional Shares” and together with the Initial Shares, the “Shares”) at a purchase price of $0.60, for an aggregate consideration of US$250,000 (the “Additional Subscription Proceeds”), all pursuant to the terms and conditions set forth in this Subscription Agreement.

1.5 Subject to the terms hereof, this Subscription Agreement will be effective upon receipt by the Company of the Subscription Proceeds.

1.6 Within seven (7) days of from the receipt of the Subscription Proceeds or the Additional Subscription Proceeds by the Company, as applicable, the Company shall deliver to the Investor book entry confirmation representing the number of Shares purchased by the Investor. The Shares shall be registered on the books of the Company as follows: Y.M.Y Industry Ltd. (Israeli Company No. 512680539), of 38 Yefet St., Tel Aviv-Yafo, Israel.

2. Payment of Subscription Proceeds and Additional Subscription Proceeds

3. Documents/Deliveries Required from the Investor

3.3 The Investor will pay/deliver the Subscription Proceeds and the Additional Subscription Proceeds, as applicable, to the Company, as provided in Section 2 above subject to the Company’s execution and acceptance of this Subscription Agreement.

4. Acknowledgements of Investor

4.1 The Investor acknowledges and agrees that:

(i)	the Shares being offered have not been registered under the Act, or under any state securities or “blue sky” laws of any state of the United States, and, unless so registered, the Shares may neither be offered nor sold in the United States or, directly or indirectly, to U.S. Persons, as that term is defined in Rule 902 of Regulation S under the Act, except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Act;

(ii)	the Investor acknowledges that the Company has not undertaken, and will have no obligation, to register the under the Act;

(iii)	the decision to execute this Subscription Agreement has not been based upon any oral or written representation as to fact or otherwise made by or on behalf of the Company, and such decision is based entirely upon a review of information (the receipt of which is hereby acknowledged) which has been filed by the Company with the SEC under the Securities Exchange Act of 1934 (collectively, the “Exchange act Reports”);

(iv)	no securities commission or similar regulatory authority has reviewed or passed on the merits of an investment in the Shares;

(v)	there is no government or other insurance covering any investment in the Shares;

(vi)	there are risks associated with an investment in the Shares, as more fully described in certain information forming part of the Exchange Act Reports;

(vii)	the Investor has had a reasonable opportunity to ask questions of and receive answers from the Company in connection with the Offering and to obtain additional information, to the extent possessed or obtainable without unreasonable effort or expense, necessary to verify the accuracy of the information about the Company;

(viii)	the books and records of the Company were available upon reasonable notice for inspection, subject to certain confidentiality restrictions, by the Investor during reasonable business hours at its principal place of business, and all documents, records and books in connection with the distribution of the Shares hereunder have been made available for inspection by the Investor, the Investor’s attorney and/or advisor(s), if any;

(ix)	there is no guarantee that the Shares will be listed on any stock exchange or automated dealer quotation system and no representation has been made to the Investor that the Shares will be listed on any stock exchange or automated dealer quotation system;

(x)	the Shares are assignable only with the prior written consent of the Company, which consent will not be unreasonably denied, provided that any such transfer is made in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the Act or pursuant to an available exemption from the registration requirements of the Act; and

(xi)	this Subscription Agreement is not enforceable by the Investor unless it has been accepted by the Company.

5. Representations, Warranties and Covenants of the Investor

(iii) the Investor has duly executed and delivered this Subscription Agreement and it constitutes a valid and

binding agreement of the Investor enforceable against the Investor;

(iv) the Investor is not a U.S. Person;

(v) the Investor is not acquiring the Shares for the account or benefit of, directly or indirectly, any U.S. Person;

(vi) the Investor is resident of the jurisdiction set out under the heading “Name and Address of Investor” on the signature page of this Subscription Agreement;

(xi) the Investor:

(a) is able to fend for itself in connection with the Offering; and

(b) has such knowledge and experience in business matters as to be capable of evaluating the merits and risks of its prospective investment in the Company’s Shares offered hereby; and

(c) has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment;

(xiv) the Investor acknowledges that:

(a) he has not received nor is he aware of any advertisement of any of the Shares;

(b) no person has made to the Investor any written or oral representations that any person will resell or repurchase any of the Shares; and

6. Conditions Precedent.

The undertaking of the Investor shall be subject to and contingent upon the following:

6.2 The Company has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the Investor enforceable against the Investor.

7. Acknowledgement and Waiver

8. Restrictive Legend on Subject Securities

NONE OF THE SHARES HAVE BEEN REGISTERED UNDER THE ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE ACT.

9. Costs

10. Governing Law

11. Survival

12. Assignment

This Subscription Agreement is transferable or assignable only with the prior written consent of the Company, which consent will not be unreasonably denied.

13. Severability

14. Entire Agreement

15. Notices

16. Counterparts and Electronic Means

IN WITNESS WHEREOF the Investor has duly executed this Subscription Agreement as of the date of

acceptance by the Company.

Y.M.Y Industry Ltd.
(Name of Investor)

/s/: Y.M.Y Industry Ltd.
(Signature of Investor)

38 Yefet St., Tel Aviv-Yafo, Israel
(Address of Investor)

A C C E P T A N C E

The above-mentioned Subscription Agreement in respect of the Shares is hereby accepted by TechCare Corp. DATED this 7^thday of August, 2018. TechCare Corp.

/s/: Doron Biran
Name: Doron Biran Title:
CEO

EX-10.5 5 ex10-5.htm

TECHCARE CORP.

(A Delaware corporation)

FIRST AMENDMENT TO SUBSCRIPTION AGREEMENT DATED AUGUST 8, 2018

DATED: October 28th, 2018 (the “Effective Date”)

WHEREAS	Y.M.Y Industry Ltd. (Israeli Company No. 512680539), of 38 Yefet St., Tel Aviv-Yafo, Israel (the “Investor”) has subscribed for and purchased 645,995 shares of common stock, par value $0.0001 (the “Shares”) offered by TechCare Corp., a Delaware corporation with offices located at 1140 Avenue of the Americas, New York, NY 10036 (the “Company”), at a purchase price per share of US$ $0.387 (the “Original Share Purchase Price”), for an aggregate consideration of US$250,000 (the “Original Investment Amount”), all pursuant to the terms and conditions set forth in a certain subscription agreement dated August 8, 2018 (the “Subscription Agreement”); and

WHEREAS	Under the subscription Agreement, the Investor was further entitled, but not obligated, until the twelve month anniversary thereof, to subscribe for, and purchase, 416,667 additional Shares of the Company, at a purchase price of $0.60, for an aggregate consideration of US$250,000, valid thru August 7, 2018, all pursuant to the terms and conditions set forth in this Subscription Agreement; and

WHEREAS	On September 25, 2018, the Company’s board of directors has adopted a resolution, pursuant to which any investor participating in this current financing round, shall be entitled, but not obligated, to increase its investment in the Company to US$500,000 or beyond, and thereby, be entitled to a discounted price per share of $0.261 (respectively: the “New Share Purchase Price” and the Discount”), which will apply both to its Original Investment Amount and to the additional amount so invested; and

WHEREAS	The Investor wishes to increase its Original Investment Amount, in consideration for the Discount;

Now Therefore, in consideration of the mutual promises set forth in this Agreement, the Parties hereby agree, represent and undertake as follows:

1. The Offering

1.1 On the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, The Investor hereby agrees to subscribe for and purchase an aggregate total of 1,915,708 shares of common stock, par value $0.0001 (the “Initial Shares”) offered by the Company, at a purchase price per share of US$ 0.261 (the “Share Purchase Price”), for an aggregate consideration of US$500,000 (the “Subscription Proceeds”), as of the date hereof, all pursuant to the terms and conditions set forth in this Subscription Agreement.

1.2 In addition, on the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement, the Investor shall be entitled, but not obligated, until the twelve month anniversary of the date hereof, to subscribe for, and purchase, 833,333 additional Shares of TechCare Corp. (the “Additional Shares”) at a purchase price of $0.60, for an aggregate consideration of US$250,000 (the “Additional Subscription Proceeds”), all pursuant to the terms and conditions set forth in the Subscription Agreement and this Amendment.

As the Investor has already subscribed for and purchased 645,995 Shares at a purchase price per share of US$ 0.387 (the “Share Purchase Price”), for an aggregate consideration of US$250,000 and received the option to subscribe for and purchase 416,667 additional Shares of the Company, at a purchase price of $0.60, the following provisions shall apply:

(a) the Investor shall transfer the outstanding balance of US$250,000 to the Company; (b) the Company shall issue 957,854 Shares to the Investor, representing the New Share Purchase Price; (c) the Company shall issue the Investor 311,859 additional Shares for the aggregate par value, representing the effectuation of the Discount with respect to the Original Investment Amount pursuant to the Subscription Agreement (i.e. a total of 957,854 shares to be issued at the New Share Purchase Price minus 645,995 already issued pursuant to the Subscription Agreement, at the Original Share Purchase Price); and (d) the Company shall grant the Investor with the option subscribe for, and purchase, 416,667 additional Shares of the Company, at a purchase price of $0.60, for an aggregate consideration of US$250,000, valid thru October 27, 2019.

1.5 Subject to the terms hereof, this Subscription Agreement will be effective upon receipt by the Company of the Subscription Proceeds.

1.6 Within seven (7) days of from the receipt of the Subscription Proceeds or the Additional Subscription Proceeds by the Company, as applicable, the Company shall deliver to the Investor book entry confirmation representing the number of Shares purchased by the Investor. The Shares shall be registered on the books of the Company as follows: Y.M.Y Industry Ltd. (Israeli Company No. 512680539), of 38 Yefet St., Tel Aviv-Yafo, Israel.

2. Payment of Subscription Proceeds and Additional Subscription Proceeds

3. Documents/Deliveries Required from the Investor

4. Acknowledgements of Investor

4.1 The Investor acknowledges and agrees that:

(ii) the Investor acknowledges that the Company has not undertaken, and will have no obligation, to register the under the Act;

(iv) no securities commission or similar regulatory authority has reviewed or passed on the merits of an investment in the Shares;

(v) there is no government or other insurance covering any investment in the Shares;

(vi) there are risks associated with an investment in the Shares, as more fully described in certain information forming part of the Exchange Act Reports;

(xi) this Subscription Agreement is not enforceable by the Investor unless it has been accepted by the Company.

5. Representations, Warranties and Covenants of the Investor

(iii) the Investor has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the Investor enforceable against the Investor;

(iv) the Investor is not a U.S. Person;

(v) the Investor is not acquiring the Shares for the account or benefit of, directly or indirectly, any U.S. Person;

(vi) the Investor is resident of the jurisdiction set out under the heading “Name and Address of Investor” on the signature page of this Subscription Agreement;

(xi) the Investor:

(a) is able to fend for itself in connection with the Offering; and

(b) has such knowledge and experience in business matters as to be capable of evaluating the merits and risks of its prospective investment in the Company’s Shares offered hereby; and

(c) has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment;

(xiv) the Investor acknowledges that:

(a) he has not received nor is he aware of any advertisement of any of the Shares;

(b) no person has made to the Investor any written or oral representations that any person will resell or repurchase any of the Shares; and

6. Conditions Precedent.

The undertaking of the Investor shall be subject to and contingent upon the following:

6.2 The Company has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the Investor enforceable against the Investor.

7. Acknowledgement and Waiver

8. Restrictive Legend on Subject Securities

9. Costs

10. Governing Law

11. Survival

12. Assignment

This Subscription Agreement is transferable or assignable only with the prior written consent of the Company, which consent will not be unreasonably denied.

13. Severability

14. Entire Agreement

15. Notices

16. Counterparts and Electronic Means

IN WITNESS WHEREOF the Investor has duly executed this Subscription Agreement as of the date of acceptance by the Company.

Y.M.Y Industry Ltd.
(Name of Investor)

/s/: Y.M.Y Industry Ltd
(Signature of Investor)

38 Yefet St., Tel Aviv-Yafo, Israel
(Address of Investor)

A C C E P T A N C E

The above-mentioned Subscription Agreement in respect of the Shares is hereby accepted by TechCare Corp. DATED this 28th day of October, 2018.

TechCare Corp.

/s/: Doron Biran___
Name:	Doron Biran
Title:	CEO

EX-31.1 6 ex31-1.htm

Exhibit 31.1

TechCare Corp.

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Doron Biran, certify that:

1. I have reviewed this quarterly report on Form 10-Q of TechCare Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Doron Biran
	Doron Biran, Chief Executive Officer

Date:	November 13, 2018

EX-31.2 7 ex31-2.htm

Exhibit 31.2

TechCare Corp.

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Nir Shemesh, certify that:

1. I have reviewed this quarterly report on Form 10-Q of TechCare Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Nir Shemesh
	Nir Shemesh, Chief Financial Officer

Date:	November 13, 2018

EX-32.1 8 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF

THE SARBANES-OXLEY ACT

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of TechCare Corp. (the “Company”) hereby certifies to such officer’s knowledge that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Doron Biran
Doron Biran, Chief Executive Officer

Dated: November 13, 2018

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-32.2 9 ex32-2.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF

THE SARBANES-OXLEY ACT

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Nir Shemesh
Nir Shemesh, Chief Financial Officer

Dated: November 13, 2018

EX-101.INS 10 tecr-20180930.xml XBRL INSTANCE FILE 0001498067 2018-01-01 2018-09-30 0001498067 2018-09-30 0001498067 2017-12-31 0001498067 2016-12-31 0001498067 TECR:EmployeesMember 2017-03-01 2017-03-31 0001498067 TECR:NonEmployeesMember 2017-03-01 2017-03-31 0001498067 2017-01-01 2017-09-30 0001498067 TECR:OEMAgreementMember TECR:OEMDistributorMember 2017-01-01 2017-12-31 0001498067 2017-09-30 0001498067 TECR:NonEmployeesMember 2017-01-31 0001498067 TECR:NonEmployeesMember 2017-12-31 0001498067 TECR:EmployeesAndDirectorsMember 2017-12-31 0001498067 TECR:OEMAgreementMember TECR:OEMDistributorMember 2017-06-22 2017-06-23 0001498067 2017-06-22 2017-06-23 0001498067 2017-01-01 2017-03-31 0001498067 2017-07-01 2017-09-30 0001498067 TECR:EmployeesAndDirectorsMember 2018-01-01 2018-09-30 0001498067 TECR:NonEmpolyeesMember 2018-07-01 2018-09-30 0001498067 TECR:MarketingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001498067 TECR:NonEmpolyeesMember srt:MinimumMember 2018-07-01 2018-09-30 0001498067 TECR:NonEmpolyeesMember srt:MaximumMember 2018-07-01 2018-09-30 0001498067 TECR:EmployeesAndDirectorsMember srt:MinimumMember 2018-01-01 2018-09-30 0001498067 TECR:EmployeesAndDirectorsMember srt:MaximumMember 2018-01-01 2018-09-30 0001498067 TECR:NonEmployeesMember 2018-01-01 2018-09-30 0001498067 TECR:EmployeesAndDirectorsMember 2018-09-30 0001498067 TECR:NonEmployeesMember 2018-09-30 0001498067 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001498067 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001498067 TECR:MarketingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001498067 TECR:OEMAgreementMember TECR:OEMDistributorMember 2018-01-01 2018-09-30 0001498067 TECR:OEMAgreementMember TECR:OEMDistributorMember 2018-09-30 0001498067 us-gaap:IsraelTaxAuthorityMember 2018-09-30 0001498067 TECR:JanuaryOneTwoThousandAndEighteenMember 2017-12-21 2017-12-22 0001498067 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001498067 us-gaap:CommonStockMember 2018-09-30 0001498067 TECR:CommonStockOneMember 2018-01-01 2018-09-30 0001498067 TECR:CommonStockOneMember 2018-09-30 0001498067 2017-01-01 2017-12-31 0001498067 2018-07-01 2018-09-30 0001498067 2018-11-12 0001498067 srt:ScenarioPreviouslyReportedMember 2017-09-30 0001498067 srt:RestatementAdjustmentMember 2017-09-30 0001498067 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-09-30 0001498067 srt:RestatementAdjustmentMember 2017-01-01 2017-09-30 0001498067 srt:ScenarioPreviouslyReportedMember 2017-07-01 2017-09-30 0001498067 srt:RestatementAdjustmentMember 2017-07-01 2017-09-30 0001498067 TECR:CommonStockTwoMember 2018-01-01 2018-09-30 0001498067 TECR:CommonStockTwoMember 2018-09-30 0001498067 TECR:NonEmployeesMember TECR:ConsultingAgreementMember 2018-07-01 2018-09-30 0001498067 TECR:NonEmployeesMember TECR:ConsultingAgreementOneMember 2018-07-01 2018-09-30 0001498067 TECR:NonEmployeesMember TECR:ConsultingAgreementTwoMember 2018-07-01 2018-09-30 0001498067 TECR:NonEmployeesMember srt:MinimumMember 2017-03-01 2017-03-31 0001498067 TECR:SubscriptionAgreementMember us-gaap:InvestorMember 2018-06-27 2018-06-28 0001498067 TECR:SubscriptionAgreementMember us-gaap:InvestorMember 2018-06-28 0001498067 TECR:BoardOfDirectorsMember 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember currency:ILS 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember currency:ILS srt:MaximumMember 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember srt:MaximumMember 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember currency:ILS TECR:AutomobileExpensesAndOtherCustomarySocialBenefitsMember 2018-07-15 2018-07-16 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember TECR:AutomobileExpensesAndOtherCustomarySocialBenefitsMember 2018-07-15 2018-07-16 0001498067 TECR:NonEmployeesMember srt:MaximumMember 2017-03-01 2017-03-31 0001498067 us-gaap:IsraelTaxAuthorityMember 2018-01-01 2018-09-30 0001498067 us-gaap:IsraelTaxAuthorityMember 2017-01-01 2017-12-31 0001498067 TECR:NonEmpolyeesMember 2018-01-01 2018-09-30 0001498067 TECR:MrBiranMember TECR:ServiceAgreementMember TECR:AutomobileExpensesAndOtherCustomarySocialBenefitsMember 2018-07-16 0001498067 us-gaap:CommonStockMember TECR:InvestmentAgreementsMember 2018-07-01 2018-09-30 0001498067 us-gaap:CommonStockMember TECR:InvestmentAgreementsMember 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockOneMember 2018-07-01 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockOneMember 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockTwoMember 2018-07-01 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockTwoMember 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockThreeMember 2018-07-01 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockThreeMember 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockFourMember 2018-07-01 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockFourMember 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockFiveMember 2018-07-01 2018-09-30 0001498067 TECR:InvestmentAgreementsMember TECR:CommonStockFiveMember 2018-09-30 0001498067 TECR:SubscriptionAgreementMember us-gaap:InvestorMember 2018-08-07 2018-08-08 0001498067 TECR:SubscriptionAgreementMember us-gaap:InvestorMember 2018-08-08 0001498067 TECR:SubscriptionAgreementMember us-gaap:SubsequentEventMember 2018-10-27 2018-10-28 0001498067 TECR:SubscriptionAgreementMember us-gaap:SubsequentEventMember 2018-10-28 0001498067 us-gaap:SubsequentEventMember 2018-10-28 0001498067 TECR:SubscriptionAgreementMember 2018-08-01 2018-08-31 0001498067 TECR:SubscriptionAgreementMember us-gaap:SubsequentEventMember srt:MaximumMember 2018-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure TechCare Corp. 0001498067 10-Q 2018-09-30 false --12-31 Non-accelerated Filer Q3

384495

589818

275041

84282

244212

105818

190375

160620

29755

958573

740399

274657

244902

29755

21564 13764 10403 10403

133365

95984

99744

166674

122035

122218

1125247

862434

396875

367120

29755

252376

106362

137780

84719

88751

87192

444555

327583

407692

472197

351005

428876

2995

2584

2177

8564286

6945151

6026641

6970542

-943901

-8086011

-6571083

-6216844

-7190500

973656

653050

511429

-32001

-61756

29755

1125247

862434

396875

367120

29755

111780

104777

107061

0.0001

10000000

500000000

29949096

25835401

21776762

29949096

25835401

21776762

191316

263268

83030

143400

872874

-609606

131765

-48735

-132470 182720 -93430 182720 -93430

1488663

2528646

388480

647121

3497454

-968808

399677

-11197

-1514928

-2504151

-383176

-656231

-3477807

973656

-394373

11197

-4848

4848

2504151

383176

3472959

-968808

394373

-11197

-0.05

-0.12

-0.02

-0.16

0.04

-0.018

-0.05

-0.12

-0.02

-0.16

0.04

-0.022

31709944

21722199

21752409

32529717

21722199

21752409

31807036

21722199

22018967

32529717

21722199

22018967

-7003

-10058

2344

8702

-10058

-2344

1507925

2494093

385520

664933

3467749

-973656

396717

-11197

27544

1222920

943901

1119125

103795

14300

52000

65000

17900

5000

16500

-9329

10193

151413

-60512

-1809151

-1065582

-28514

-11821

1592000

878250

900000

1622000

878250

-205323

-190759

NOTE 1: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   A. Nature of operations   TechCare Corp. (“Techcare” or the “Company”), formally known as BreedIT Corp. (“BreedIt”) was incorporated under the laws of the State of Delaware on May 26, 2010. The Company’s common stock is traded in the United States on the OTCQB Market under the ticker symbol “TECR”.   On February 8, 2016, the Company signed a Merger Agreement with Novomic Ltd. (“Novomic”), a private company incorporated under the laws of the State of Israel. The closing of the Merger took place on August 9, 2016 pursuant to which Novomic became a wholly-owned subsidiary of the Company. The Merger was structured as a reverse Merger.   Novomic was incorporated as a private company in Israel in 2009. Since inception, Novomic has been a technology company engaged in the design, development and commercialization of a unique delivery platform utilizing vaporization of various natural compounds for multiple health, beauty and wellness applications. Novomic’s delivery platform is proprietary and patented.   Novomic’s first product is Novokid® - an innovative home use device which vaporizes a natural, plant-based, pesticides and silicone-free compound that effectively treats head lice and eggs. The Novokid® kit includes a vaporizer, treatment capsules and treatment cap alongside ancillary components. Novokid® is currently being sold in Israel and the Netherlands.   Novomic is currently working on the research and development of future product offerings for its delivery platform, including Shine, a revolutionary cosmetic device for the treatment and rejuvenation of the hair and scalp.   Going Concern   During the nine months period ended September 30, 2018, the Company had a comprehensive loss of approximately $1.5 million. As of September 30, 2018, the Company had accumulated losses of approximately $8 million.   Based on the projected cash flows and Company’s cash balances as of September 30, 2018, Company’s management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue advancing its activities including the development, manufacturing and marketing of its products for a period of at least 12 months from the date of issuance of these financial statements. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.   Management’s plans include the continued commercialization of the products, continue taking cost reduction steps and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to reduce activities, curtail or cease operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.   B. Summary of significant accounting policies   The accounting policies adopted are consistent with those of the previous financial year.   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements and condensed footnotes have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“GAAP”), for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for fair statement of results for the interim periods presented have been included. The results of operations for the nine and the three months ended September 30, 2018 are not necessarily indicative of the results to be expected for the year or for other interim periods or for future years. The consolidated balance sheet as of December 31, 2017 is derived from audited financial statements as of that date; however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on April 2, 2018.   Principles of Consolidation   The accompanying consolidated financial statements include the accounts of TechCare, and its subsidiary, Novomic. All intercompany balances and transactions have been eliminated in consolidation.   Revenue Recognition   Effective January 1, 2018, the Company adopted the new accounting standard related to the recognition of revenue in contracts with customers. Since the Company had no revenues prior to January 1, 2018, the new standard had no impact on revenues and results of operations for prior periods.   The Company derives revenues from sales of its product Novokid directly or indirectly through its distributors in the Netherlands and in Israel.   The Company determines revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 38px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Identification of the contract, or contracts, with a customer.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Identification of the performance obligations in the contract.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Determination of the transaction price.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Allocation of the transaction price to the performance obligations in the contract.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Recognition of revenue when, or as, the Company satisfies a performance obligation.</td></tr> </table>   Revenue is measured as the amount of consideration expected to receive in exchange for transferring goods to the end customer or to the distributor.The Company also considers products that might be returned mostly based on the terms stipulated in the agreements with its distributors.The Company recognize the amount received or receivable that is expected to be returned as a refund liability,representing its obligation to return the clients’ consideration.   The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.   Revenue from products are recognized when the customer or the distributor has obtained control of the goods (for the Company’s current arrangements, this is at the point in time) based on the shipping terms. The Company recognizes revenue on sales to distributors upon shipment of the goods, when the distributor has economic substance apart from the Company and the distributor is considered the principal for the transaction with the end-user client.

NOTE 2: NEW ACCOUNTING PRONOUNCEMENTS   Accounting Pronouncements Adopted in Current Period   In May 2014, and in following related amendments, the Financial Accounting Standards Board (the “FASB”) issued a new comprehensive revenue recognition guidance on revenue from contracts with customers ( the “Standard”) that will supersede the current revenue recognition guidance. The Standard provides a unified model to determine when and how revenue is recognized. The core principle of the Standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements since the Company had no revenues prior to 2018.   In January 2016, the FASB issued an Accounting Standards Update (an “ASU”) which changes to the current measurement model primarily affects all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Under the new ASU equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) with readily determinable fair values will be measured at fair value through earnings. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements.   In November 2016, the FASB issued an ASU which requires entities to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this guidance on January 1, 2018, which resulted in no impact on its consolidated financial statements.   In June 2018, the FASB issued an ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which previously included share-based payments to employees only) to include share based payments issued to nonemployees for goods or services, with certain exceptions. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 commencing July 1, 2018, with no impact on its consolidated financial statements.   Recently Issued Accounting Pronouncements Not Yet Adopted   In February 2016, the FASB issued a new ASU which revises lease accounting guidance. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability for all leases, other than leases that meet the definition of a short-term lease. The liability and the right-of-use asset arising from the lease will be measured as the present value of the lease payments. In addition, this guidance requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. The new standard is effective for fiscal year beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach, with certain practical expedients. The Company is currently evaluating the impact of the adoption of the new lease accounting guidance on its consolidated financial statements.

NOTE 3: RESTATEMENT OF 2017 CONDENSED CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS   As discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, during the preparation of the 2017 annual financial statements, the Company became aware of misstatements in its condensed consolidated financial statements for the quarter ended March 31, 2017, the six months ended June 30, 2017, and the nine months ended September 30, 2017, that were included in each of the Company’s 2017 Form 10-Qs. The misstatement stemmed from an erroneous recording of additional stock compensation expense of $943,901 during the three months ended March 31, 2017 related to certain fully vested awards that were granted in December 31, 2016, and were properly fully expensed in 2016. As a result, the Company’s previously reported net loss for each of the three aforementioned periods in 2017 was overstated by this amount. The Board of Directors and the Company concluded that due to this error the condensed consolidated financial statements for each of these periods was materially misstated and should be restated (the Restatement).   The Restatement also corrects certain other misstatements during the 2017 interim periods, including (i) an error related to the accounting for advances to suppliers that were previously expensed that impacted the quarters ended June 30, 2017, and September 30, 2017, and (ii) errors in the classification of certain expenses within the consolidated statements of operations and comprehensive loss which impacts classification only and does not impact the total net loss or comprehensive loss reported for any of the periods.   The Restatement does not result in a change to the Company’s previously reported total amounts of net cash flows from operating activities, investing activities, or financing activities. There was no impact to net change in cash and cash equivalents for any previously reported periods. Certain corrections of classifications within the operating cash flow section were impacted by the Restatement.   Condensed consolidated balance sheet as of September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Current assets:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 10pt; line-height: 107%">Cash and cash equivalents</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">84,282</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">84,282</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Other receivables</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">160,620</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">190,375</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Total current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">244,902</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">274,657</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-current assets:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Severance pay fund</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10,403</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10,403</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Long-term deposit</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,071</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,071</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">99,744</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">99,744</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total non-current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">122,218</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">122,218</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 30pt; line-height: 107%">Total assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">367,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,875</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Liabilities and Stockholders’ Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Accounts payable and accrued expenses</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">137,780</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">137,780</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Note payable</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">87,192</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">87,192</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 30pt; line-height: 107%">Total current liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407,692</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407,692</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-current liability:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Liability for severance pay</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,184</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,184</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 30pt; line-height: 107%">Total liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">428,876</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">428,876</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Commitments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stockholders’ equity:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,177</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,177</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Accumulated other comprehensive income</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">107,061</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">107,061</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Additional paid-in capital</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,970,542</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(943,901</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,026,641</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Stock to be issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">48,964</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">48,964</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Accumulated deficit</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(7,190,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">973,656</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(6,216,844</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 30pt; line-height: 107%">Total capital deficiency</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(61,756</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(32,001</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total liabilities and capital deficiency</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">367,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,875</td> <td style="line-height: 107%"> </td></tr> </table>   Condensed consolidated statement of operations and comprehensive loss for the nine month period ended September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">872,874</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">(609,606</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">263,268</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value of option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Marketing, general and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,441,860</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(359,202</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,082,658</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Operating loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,497,454</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(968,808</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,528,646</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Financial income, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,495</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,495</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Loss before income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,472,959</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(968,808</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Tax expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,848</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(4,848</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,477,807</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss per common stock:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.16</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.12</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.16</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.12</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average number of common stock outstanding:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Comprehensive loss:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,477,807</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other comprehensive income attributable to foreign currency translation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">10,058</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">10,058</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,467,749</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,494,093</td> <td style="line-height: 107%"> </td></tr> </table>   Condensed consolidated statement of operations and comprehensive loss for the three month period ended September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">131,765</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">(48,735</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">83,030</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value of option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(93,430</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(93,430</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Marketing, general and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">361,342</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">37,538</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">398,880</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Operating loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">399,677</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">388,480</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Financial income, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,304</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,304</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Loss before income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Tax expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss per common stock:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.018</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.018</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.022</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.022</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average number of common stock outstanding:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,752,409</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,752,409</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,018,967</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,018,967</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Comprehensive loss:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other comprehensive expense attributable to foreign currency translation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,344</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,344</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,717</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">385,520</td> <td style="line-height: 107%"> </td></tr> </table>

NOTE 4: STOCKHOLDERS’ EQUITY   Share capital   During the nine months ended September 30, 2018, the Company entered into several agreements, under which the Company raised an aggregate amount of $ 1,622,000, as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%"> </td> <td style="width: 48px; text-align: justify; line-height: 107%">a)</td> <td style="text-align: justify; line-height: 107%">1,291,990 shares of its common stock at a purchase price of $0.387 for a total consideration of $500,000 and warrants to purchase up to 645,995 stock with an exercise price of $0.387, exercisable until June 30, 2018. The warrants expired on June 30, 2018.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">b)</td> <td style="text-align: justify; line-height: 107%">1,033,592 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $400,000, and warrants to purchase up to 516,796 stock with an exercise price of $0.387, exercisable until September 30, 2018. The warrants expired on September 30, 2018.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">c)</td> <td style="text-align: justify; line-height: 107%">108,527 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $42,000, and warrants to purchase up to 70,000 stock with an exercise price of $0.60, exercisable until June 17, 2019.</td></tr> </table>   Investment agreements signed during the three months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 48px; line-height: 107%">d)</td> <td style="text-align: justify; line-height: 107%">645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until June 27, 2019.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">e)</td> <td style="text-align: justify; line-height: 107%">645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">f)</td> <td style="text-align: justify; line-height: 107%">129,199 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $50,000, and warrants to purchase up to 83,333 stock with an exercise price of $0.6, exercisable until August 7, 2019.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">g)</td> <td style="text-align: justify; line-height: 107%">258,398 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $100,000, and warrants to purchase up to 166,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">h)</td> <td style="text-align: justify; line-height: 107%">77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 shares of common stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet issued the shares of common stock and, therefore, recorded stock to be issued in the amount of $30,000 in the consolidated financial statements.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">i)</td> <td style="text-align: justify; line-height: 107%">77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet received the investment proceeds and therefore had not issued the shares of common stock for such investment.</td></tr> </table>   Stock-Based Compensation to employees and directors   Stock based awards are accounted for using the fair value method in accordance with ASC 718, Shared Based Payment. The Company’s primary type of stock-based compensation consists of stock options to directors, employees and officers. The Company uses Black-Scholes option pricing model in valuing options.   During the nine months ended September 30, 2018 the Company had not granted any options to employees and directors.   During March 2017, the Company granted to certain employees options to purchase 869,596 of the Company’s common stock for an exercise price of $0.0001. The options granted were fully vested on the date of the grant and exercisable into the Company’s common stock at a 1:1 ratio for 2.5 years from the date of the grant.   The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">1.54</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.5-5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The Company based the risk-free interest rate on the U.S. Treasury yield curve. The expected term in years represents the period of time that the awards granted are expected to be outstanding. The assumption for dividend yield is zero because the Company has not historically paid dividends nor does it expect to do so in the foreseeable future. The volatility was based on the historical stock volatility of several peer companies, as the Company has limited trading history to use the volatility of its own common stock.   A summary of the stock option activity for employees and directors for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">U.S Dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Options outstanding at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">2,640,334</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">0.0001</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,640,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,640,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td></tr> </table>   Stock-based compensation expenses related to employee awards, included in the Company’s statements of operations and comprehensive loss, were allocated as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended  September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Restated (see note 3)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">                -</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">103,795</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Marketing ,general and administrative</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,119,125</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,222,920</td> <td style="line-height: 107%"> </td></tr> </table>   Stock-Based Compensation to non-employees – Options and Warrants   The Company early adopted ASU 2018-07 commencing July 1, 2018, with no impact on its consolidated financial statements. Prior to the adoption of ASU 2018-07 stock options issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the options. The fair value of the options granted were measured on a final basis at the end of the related service period and were recognized over the related service period using the straight line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, over the requisite service period, which is the vesting period of the respective award.   In the second quarter of 2018, as part of consulting agreements, the Company granted options to non-employees, as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">1)</td> <td style="text-align: justify; line-height: 107%">83,393 options exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on December 1, 2018, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">2)</td> <td style="text-align: justify; line-height: 107%">83,393 options to a related party exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on January 1, 2019, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">3)</td> <td style="text-align: justify; line-height: 107%">436,349 options to a related party exercisable to purchase 436,349 shares of common stock of the Company, at an exercise price of $0.387 per option. The options will be vested in accordance with the following vesting periods: 33.33% of the options will be exercisable on January 1, 2019, and the remaining 66.67% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 8 quarters.</td></tr> </table>   The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.65%-2.85</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 78%; text-align: justify; line-height: 107%">Expected shares price volatility</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 19%; text-align: right; line-height: 107%">70</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The Company based the risk-free interest rate on the U.S. Treasury yield curve. The expected term in years represents the period of time that the awards granted are expected to be outstanding. The assumption for dividend yield is zero because the Company has not historically paid dividends nor does it expect to do so in the foreseeable future. The volatility was based on the historical stock volatility of several peer companies, as the Company has limited trading history to use the volatility of its own common stock.   During January 2017, as part of a consulting agreement, the Company granted to a non-employee warrants exercisable to purchase 100,000 of the Company’s common stock at an exercise price of $1.50 per warrant exercisable for a period of 24 months commencing on the date of the agreement, fully vested on the date of the grant.   During March 2017, the Company granted to a non-employee options to purchase 521,065 of the Company’s common stock for an exercise price of $0.0001. The options granted were fully vested on the date of the grant and exercisable into the Company’s common stock at a 1:1 ratio for 5 years from the date of the grant.   The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%; text-align: justify; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">1.54</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2-5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   A summary of the stock option activity related to non-employees, for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">U.S Dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Options outstanding at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">621,065</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">0.2416</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">603,135</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2800</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,224,200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2605</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">621,065</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2416</td> <td style="line-height: 107%"> </td></tr> </table>   Stock-based compensation expenses in the amount of $27,544 included in the Company’s statements of operations and comprehensive loss for the nine months period ended September 30, 2018 recorded in marketing, general and administrative.

NOTE 5: OEM DISTRIBUTION AGREEMENT   On June 23, 2017, the Company entered into an OEM agreement (the “OEM Agreement”) with a medical device and wellness applications company based in the United States (the “OEM Distributor”), according to which the OEM Distributor will manufacture, distribute and sell the Company’s Novokid head lice treatment products in the United States, Canada, Brazil, Argentina, Costa Rica and Colombia, all on an exclusive basis, pursuant to and in accordance with the terms and conditions set forth in the OEM Agreement, including minimum royalties commitments. The OEM Distributor will be solely responsible for obtaining and maintaining the approval from the US Food and Drug Administration (the “FDA”) and shall bear all costs related to such approval. The Company, through its OEM Distributor, has been communicating with the FDA regarding Novokid’s designation as a medical device. An Application to the FDA Office of Combination (OCP division) is under preparation.   As of the date of these financial statements, an FDA approval was not obtained, hence, the Company did not generate any revenues from the OEM agreement.   As part of the OEM Agreement, the OEM Distributor paid a royalty advance of $10,000 and also an amount of $140,000 which is held in an escrow account, until the Company completes certain milestones, as described in the OEM Agreement. As of September 30, 2018, the milestones have not been achieved.   Also, as part of the OEM Agreement, the Company granted the OEM Distributor an option to purchase up to 9.09% of the Company’s common stock for a total consideration of up to $900,000,exercisable until January 15, 2018.   The fair value of the option as of June 23, 2017 (initial recognition) amounted to $432,518.The key assumptions used in the options’ valuation was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1.14</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.56</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The fair value of the option as of December 31, 2017 amounted to $132,470.The key assumptions used in the options’ valuation was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1.28</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The option expired on January 15, 2018.

NOTE 6: INCOME TAXES   a. Basis of taxation   The Company and its subsidiary are taxed under the domestic tax laws of the jurisdiction of incorporation of each entity (United States and Israel).   b. Carryforward Tax Losses   Carryforward Tax Losses of the US Company as of September 30, 2018 amounted to approximately $0.4 million. Carryforward Tax Losses of the Israeli subsidiary amounted to approximately $5.1 million. A full valuation allowance was created against these carry forward tax losses since the realization of any future benefit from these net operating losses cannot be sufficiently assured at September 30, 2018.   c. Corporate tax rates   The regular corporate tax rate in Israel in 2017 is 24% and 23% in 2018.   On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “TCJA”), which among other reduces the federal corporate tax rate from 35% to 21%, effective January 1, 2018.   The Company has no impact of the TCJA on these condensed consolidated financial statements.

NOTE 7: LOSS PER SHARE   Loss per share is based on the loss that is attributed to the stockholders holding common stock, divided by the weighted average number of common stock in issue during the period.   For purposes of the calculation of the diluted loss per share, the Company adjusts the weighted average number of common stock using the treasury stock method assuming conversion of all of the dilutive potential stock. The potential stock are taken into account only if their effect is dilutive (increases loss per share).

NOTE 8: FAIR VALUE OF FINANCIAL INSTRUMENTS   The carrying amount of the Company’s financial instruments, including cash equivalents, current assets, accounts payable and accrued liabilities and notes payables approximate their fair value, due to their short term in nature and their carrying amounts approximates the amounts expected to be received or paid.   A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The Company accounts for option liability as Level 3 since its inputs are unobservable inputs for the liability.   The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">US dollar</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">US dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%">Fair value as of January 1</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">132,470</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value recognized in statement of operations and comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(132,470</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">276,150</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Fair value as of September 30</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">276,150</td> <td style="line-height: 107%"> </td></tr> </table>

Basis of Presentation   The accompanying unaudited condensed consolidated financial statements and condensed footnotes have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“GAAP”), for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for fair statement of results for the interim periods presented have been included. The results of operations for the nine and the three months ended September 30, 2018 are not necessarily indicative of the results to be expected for the year or for other interim periods or for future years. The consolidated balance sheet as of December 31, 2017 is derived from audited financial statements as of that date; however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on April 2, 2018.

Principles of Consolidation   The accompanying consolidated financial statements include the accounts of TechCare, and its subsidiary, Novomic. All intercompany balances and transactions have been eliminated in consolidation.

Condensed consolidated balance sheet as of September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Current assets:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 10pt; line-height: 107%">Cash and cash equivalents</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">84,282</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">84,282</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Other receivables</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">160,620</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">190,375</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Total current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">244,902</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">274,657</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-current assets:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Severance pay fund</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10,403</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10,403</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Long-term deposit</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,071</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,071</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">99,744</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">99,744</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total non-current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">122,218</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">122,218</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 30pt; line-height: 107%">Total assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">367,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,875</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Liabilities and Stockholders’ Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Accounts payable and accrued expenses</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">137,780</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">137,780</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Note payable</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">87,192</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">87,192</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 30pt; line-height: 107%">Total current liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407,692</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407,692</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-current liability:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Liability for severance pay</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,184</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,184</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 30pt; line-height: 107%">Total liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">428,876</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">428,876</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Commitments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stockholders’ equity:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,177</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,177</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Accumulated other comprehensive income</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">107,061</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">107,061</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Additional paid-in capital</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,970,542</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(943,901</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,026,641</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Stock to be issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">48,964</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">48,964</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Accumulated deficit</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(7,190,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">973,656</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(6,216,844</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 30pt; line-height: 107%">Total capital deficiency</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(61,756</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(32,001</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total liabilities and capital deficiency</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">367,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">29,755</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,875</td> <td style="line-height: 107%"> </td></tr> </table>   Condensed consolidated statement of operations and comprehensive loss for the nine month period ended September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">872,874</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">(609,606</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">263,268</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value of option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">182,720</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Marketing, general and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,441,860</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(359,202</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,082,658</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Operating loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,497,454</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(968,808</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,528,646</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Financial income, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,495</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,495</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Loss before income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,472,959</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(968,808</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Tax expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,848</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(4,848</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,477,807</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss per common stock:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.16</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.12</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.16</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.12</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average number of common stock outstanding:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,722,199</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Comprehensive loss:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,477,807</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,504,151</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other comprehensive income attributable to foreign currency translation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">10,058</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">10,058</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,467,749</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(973,656</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,494,093</td> <td style="line-height: 107%"> </td></tr> </table>   Condensed consolidated statement of operations and comprehensive loss for the three month period ended September 30, 2017 (Unaudited):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As previously reported</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As Restated</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">131,765</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">(48,735</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">83,030</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value of option liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(93,430</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(93,430</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Marketing, general and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">361,342</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">37,538</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">398,880</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Operating loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">399,677</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">388,480</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Financial income, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,304</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,304</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Loss before income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Tax expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Net loss per common stock:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.018</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.018</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.022</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.022</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average number of common stock outstanding:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,752,409</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,752,409</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,018,967</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,018,967</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Comprehensive loss:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">394,373</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">383,176</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other comprehensive expense attributable to foreign currency translation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,344</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,344</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">396,717</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(11,197</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">385,520</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the stock option activity for employees and directors for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">U.S Dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Options outstanding at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">2,640,334</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">0.0001</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,640,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,640,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the stock option activity related to non-employees, for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">U.S Dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Options outstanding at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">621,065</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">0.2416</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">603,135</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2800</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,224,200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2605</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">621,065</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.2416</td> <td style="line-height: 107%"> </td></tr> </table>

The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">1.54</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.5-5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.65%-2.85</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 78%; text-align: justify; line-height: 107%">Expected shares price volatility</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 19%; text-align: right; line-height: 107%">70</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The following assumptions were applied in determining the options’ fair value on their grant date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%; text-align: justify; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">1.54</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2-5</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

31999

4170

869596

521065

603135

83393

436349

0.0001

0.2800

0.0001

0.387

P2Y6M

P5Y

621065

2640334

1224200

0.2416

0.0001

0.2605

P6M21D

P5Y

P2Y6M

P5Y

P15D

P2Y

P5Y

11745

12287

12071

6059

194995

132470

432518

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1.14</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.56</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1.28</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected shares price volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">70</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected option term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.04</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

2640334

621065

0.0001

0.2416

60000 30000 48964 48964

156240

41445

1489784

2082658

398880

522864

2441860

-359202

361342

37538

120978

310877

-7055

132470

100000

645995

516796

70000

416667

83333

166667

50000

583334

1.50

0.387

0.60

0.6

0.60

0.6

0.0154

0.0114

0.0154

0.0265

0.0285

0.0128

0.70

0.00

0.21

0.23

0.24

400000

5100000

132470

276150

-132470

276150

24495 5304 24495 5304 29949096

128842

71224

59967

19143

10342

8394

Revenue Recognition   Effective January 1, 2018, the Company adopted the new accounting standard related to the recognition of revenue in contracts with customers. Since the Company had no revenues prior to January 1, 2018, the new standard had no impact on revenues and results of operations for prior periods.   The Company derives revenues from sales of its product Novokid directly or indirectly through its distributors in the Netherlands and in Israel.   The Company determines revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 38px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Identification of the contract, or contracts, with a customer.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Identification of the performance obligations in the contract.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Determination of the transaction price.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Allocation of the transaction price to the performance obligations in the contract.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Recognition of revenue when, or as, the Company satisfies a performance obligation.</td></tr> </table>   Revenue is measured as the amount of consideration expected to receive in exchange for transferring goods to the end customer or to the distributor.The Company also considers products that might be returned mostly based on the terms stipulated in the agreements with its distributors.The Company recognize the amount received or receivable that is expected to be returned as a refund liability,representing its obligation to return the clients’ consideration.   The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.   Revenue from products are recognized when the customer or the distributor has obtained control of the goods (for the Company’s current arrangements, this is at the point in time) based on the shipping terms. The Company recognizes revenue on sales to distributors upon shipment of the goods, when the distributor has economic substance apart from the Company and the distributor is considered the principal for the transaction with the end-user client.

10000

2018-01-15

140000

TECR

1622000

1291990

1033592

108527

645995

129199

258398

77519

904393

1915708

645995

0.387

0.261

2018-06-30

2018-09-30

2019-06-17

2019-06-28

2019-06-27

2019-08-07

2019-08-21

2019-08-07

2019-10-27

Federal corporate tax rate from 35% to 21%, effective January 1, 2018.

2018

The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">US dollar</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">US dollar</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%">Fair value as of January 1</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">132,470</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Change in fair value recognized in statement of operations and comprehensive loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(132,470</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">276,150</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Fair value as of September 30</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">276,150</td> <td style="line-height: 107%"> </td></tr> </table>

173626

3318

30000

NOTE 9: RELATED PARTIES   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">(a)</td> <td style="text-align: justify; line-height: 107%">On June 28, 2018 the Company entered into a subscription agreement with an investor, pursuant to which the Company will issue 645,995 shares of its common stock at a purchase price of $0.387 for a total consideration of $250,000 and warrants to purchase up to 416,667 stock with an exercise price of $0.60, exercisable until June 28, 2019. In August 2018, the funds were received and the shares of common stock were issued.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">(b)</td> <td style="text-align: justify; line-height: 107%">On August 8, 2018 the Company entered into subscription agreements with several investors who are related parties, pursuant to which the Company issued 904,393 shares of its common stock at a purchase price of $0.387 for a total consideration of $350,000 and warrants to purchase up to 583,334 stock with an exercise price of $0.60, exercisable until August 7, 2019.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">(c)</td> <td style="text-align: justify; line-height: 107%">On July 16, 2018, the Board of Directors of the Company has appointed Mr. Doron Biran as the new Chief Executive Officer of the Company and its wholly-owned subsidiary Novomic. Pursuant to the service agreement (the “Agreement”) signed with Mr, Biran, Mr. Biran will receive a monthly compensation of NIS 52 thousand (approximately $14.3 thousand) plus VAT. In the event of a capital raise exceeding $1,000 thousand Mr. Biran will be entitled to compensation increase to a total of NIS 65 thousand (approximately $17.9 thousand). Furthermore, upon the earlier of either 24 months from the effective date of the Agreement, or a capital raise exceeding $5,000 thousand and listing of the Company on the Nasdaq Stock Market, Mr. Biran shall become an employee of the Company and shall receive a base salary of NIS 60 thousand as well as NIS 5 thousands for automobile expenses (approximately $16.5 thousand) and other customary social benefits.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Pursuant to the Agreement, Mr. Biran is entitled to options to purchase 870,958 common stock of the Company (the “Options”). The Options shall vest over a period of four years in quarterly increments, commencing on June 11, 2018, subject to continued provision of services by Mr. Biran in accordance with the Agreement. The Options shall accelerate and become fully vested in the event of a merger or acquisition of the Company at an evaluation exceeding $50 million or in the event that the Company’s traded value exceeds $50 million (each, “Acceleration Event” and together “Acceleration Events”), provided that Mr. Biran provided his services to the Company for a period of at least 12 months prior to the Acceleration Event. The exercise price of each Option shall be $0.279, equal to the volume weighted average price of the Company’s common stock during a 30 days’ period prior to the signing of Mr. Biran’s services Agreement. As of the date of the report Options were not granted yet.</td></tr> </table>

NOTE 10: SUBSEQUENT EVENT   On October 28, 2018, the Company entered into an amendment to the subscription agreement mentioned in note 4e (the “Amendment”). Pursuant to the Amendment, the investor has increased its initial investment by an additional sum of $250,000 to a total investment of $500,000 and is to be issued a total of 1,915,708 shares of common stock at a price per share of $0.261, out of which 645,995 shares of common stock were issued in August 2018. In addition, the investor was issued additional warrants to purchase up to 416,667 shares of common stock with an exercise price of $0.6, exercisable until October 27, 2019. The funds were received in November 2018.

182720 182720

0.25

0.3333

870958

1000

5000

0.279

P4Y

50000000

60000

27642

23422

21184

-6614

5229

-3485

1592

Stock-based compensation expenses related to employee awards, included in the Company’s statements of operations and comprehensive loss, were allocated as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended  September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Restated (see note 3)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Research and development expenses</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">                -</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">103,795</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Marketing ,general and administrative</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,119,125</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,222,920</td> <td style="line-height: 107%"> </td></tr> </table>

500000

400000

42000

250000

50000

100000

30000

350000

The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on December 1, 2018, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on January 1, 2019, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

The options will be vested in accordance with the following vesting periods: 33.33% of the options will be exercisable on January 1, 2019, and the remaining 66.67% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 8 quarters.

26265

-24495

-5304

9110

0.0909

107088

416667

107460

true false false

188809

90367

70964

30000

250000

500000

EX-101.SCH 11 tecr-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Restatement of 2017 Condensed Consolidated Quarterly Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - OEM Distribution Agreement link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Restatement of 2017 Condensed Consolidated Quarterly Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - OEM Distribution Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Restatement of 2017 Condensed Consolidated Quarterly Financial Statements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Restatement of 2017 Condensed Consolidated Quarterly Financial Statements - Schedule of Restatement to Prior Year Income (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Restatement of 2017 Condensed Consolidated Quarterly Financial Statements - Schedule of Restatement to Prior Year Income (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity - Schedule of Fair Values of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expenses Related to Employee Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - OEM Distribution Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - OEM Distribution Agreement - Schedule of Assumptions Used to Fair Values of Options Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Fair Value of Financial Instruments - Schedule of Reconciliation of Change Fair Value Measurement Estimated Utilizing Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 tecr-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 tecr-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 14 tecr-20180930_lab.xml XBRL LABEL FILE Title of Individual [Axis] Employees [Member] Non-Employees [Member] Type of Arrangement and Non-arrangement Transactions [Axis] OEM Agreement [Member] OEM Distributor [Member] Employees and Directors [Member] Non Employees [Member] Income Statement Location [Axis] Marketing, General and Administrative Expenses [Member] Range [Axis] Minimum [Member] Maximum [Member] Research and Development Expense [Member] Income Tax Authority, Name [Axis] Israel Tax [Member] Report Date [Axis] January 1, 2018 [Member] Equity Components [Axis] Common Stock [Member] Common Stock One [Member] Restatement [Axis] As Previously Reported [Member] Adjustment [Member] Common Stock Two [Member] Consulting Agreement [Member] Consulting Agreement One [Member] Consulting Agreement Two [Member] Subscription Agreement [Member] Related Party [Axis] Three Investors [Member] Board of Directors [Member] Mr. Biran [Member] Service Agreement [Member] Currency [Axis] Israel, New Shekels [Member] Collateral [Axis] Automobile Expenses And Other Customary Social Benefits [Member] Investment Agreements [Member] Common Stock Three [Member] Common Stock Four [Member] Common Stock Five [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Accounts receivables Inventory Other receivables Total current assets Non-current assets: Severance pay fund Long-term deposits Property and equipment, net Total non-current assets Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued expenses Refund liability Note payable Option liability Total current liabilities Non-current liability: Liability for severance pay Total liabilities Commitments Stockholders' equity: Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2018 and December 31, 2017 Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 29,949,096 and 25,835,401 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Accumulated other comprehensive income Additional paid-in capital Stock to be issued Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Research and development expenses Change in fair value of option liability Marketing, General and administrative expenses Operating loss Financial expenses (income), net Net loss Net loss per common stock: Basic Diluted Weighted average number of common stock outstanding: Basic Diluted Comprehensive loss: Net loss Other comprehensive expense (income) attributable to foreign currency translation Comprehensive loss Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock issued in relation to consulting services Stock-based compensation Changes in cash attributed to changes in operating assets and liabilities: Other receivables and prepaid expenses Accounts payable and accrued expenses Liability for severance pay Refund liability Inventory Net cash used in operating activities Cash flow from investing activities: Severance pay fund Purchase of fixed assets Investment in long-term deposit Net cash used in investing activities Cash flow from financing activities: Proceeds from issuance of common stock Proceeds from stock to be issued Net cash provided by financing activities Effect of exchange rates on cash and cash equivalents Decrease in cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Non-cash financing activity during the period: Issuance of common stock and warrants Accounting Policies [Abstract] Nature of Operations and Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] New Accounting Pronouncements Restatement of 2017 Condensed Consolidated Quarterly Financial Statements Equity [Abstract] Stockholders' Equity Contractors [Abstract] OEM Distribution Agreement Income Tax Disclosure [Abstract] Income Taxes Earnings Per Share [Abstract] Loss Per Share Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Related Party Transactions [Abstract] Related Parties Subsequent Events [Abstract] Subsequent Event Basis of Presentation Principles of Consolidation Revenue Recognition Schedule of Restatement to Prior Year Income Statement [Table] Statement [Line Items] Schedule of Fair Values of Stock Options Schedule of Stock Option Activity Schedule of Stock-based Compensation Expenses Related to Employee Awards Schedule of Assumptions Used to Fair Values of Options Valuation Schedule of Reconciliation of Change Fair Value Measurement Estimated Utilizing Level 3 Inputs Comprehensive loss Accumulated losses Stock compensation expense Total current assets Long-term deposit Total non-current assets Total assets Option liability Total current liabilities Total liabilities Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017 Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017 Total capital deficiency Total liabilities and capital deficiency Marketing, general and administrative expenses Operating loss Financial income, net Loss before income taxes Tax expenses Net loss per common stock: Basic Net loss per common stock: Diluted Weighted average number of common stock outstanding: Basic EX-101.PRE 15 tecr-20180930_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 12, 2018
Document And Entity Information
Entity Registrant Name	TechCare Corp.
Entity Central Index Key	0001498067
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		29,949,096
Trading Symbol	TECR
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 17 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 384,495	$ 589,818
Accounts receivables	173,626	3,318
Inventory	156,240	41,445
Other receivables	244,212	105,818
Total current assets	958,573	740,399
Non-current assets:
Severance pay fund	21,564	13,764
Long-term deposits	11,745	12,287
Property and equipment, net	133,365	95,984
Total non-current assets	166,674	122,035
Total assets	1,125,247	862,434
Current liabilities:
Accounts payable and accrued expenses	252,376	106,362
Refund liability	107,460
Note payable	84,719	88,751
Option liability		132,470
Total current liabilities	444,555	327,583
Non-current liability:
Liability for severance pay	27,642	23,422
Total liabilities	472,197	351,005
Commitments
Stockholders' equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2018 and December 31, 2017
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 29,949,096 and 25,835,401 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	2,995	2,584
Accumulated other comprehensive income	111,780	104,777
Additional paid-in capital	8,564,286	6,945,151
Stock to be issued	60,000	30,000
Accumulated deficit	(8,086,011)	(6,571,083)
Total stockholders' equity	653,050	511,429
Total liabilities and stockholders' equity	$ 1,125,247	$ 862,434

XML 18 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	29,949,096	25,835,401	21,776,762
Common stock, shares outstanding	29,949,096	25,835,401	21,776,762

XML 19 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 90,367		$ 188,809
Cost of revenues	71,224		128,842
Gross profit	19,143		59,967
Research and development expenses	143,400	83,030	191,316	263,268
Change in fair value of option liability		(93,430)	(132,470)	182,720
Marketing, General and administrative expenses	522,864	398,880	1,489,784	2,082,658
Operating loss	647,121	388,480	1,488,663	2,528,646
Financial expenses (income), net	9,110	(5,304)	26,265	(24,495)
Net loss	$ 656,231	$ 383,176	$ 1,514,928	$ 2,504,151
Net loss per common stock:
Basic	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.12)
Diluted	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.12)
Weighted average number of common stock outstanding:
Basic	32,529,717	21,752,409	31,709,944	21,722,199
Diluted	32,529,717	22,018,967	31,807,036	21,722,199
Comprehensive loss:
Net loss	$ 656,231	$ 383,176	$ 1,514,928	$ 2,504,151
Other comprehensive expense (income) attributable to foreign currency translation	8,702	2,344	(7,003)	(10,058)
Comprehensive loss	$ 664,933	$ 385,520	$ 1,507,925	$ 2,494,093

XML 20 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (1,514,928)	$ (2,504,151)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	(9,329)	10,193
Stock issued in relation to consulting services		70,964
Change in fair value of option liability	(132,470)	182,720
Stock-based compensation	27,544	1,222,920
Changes in cash attributed to changes in operating assets and liabilities:
Other receivables and prepaid expenses	(310,877)	7,055
Accounts payable and accrued expenses	151,413	(60,512)
Liability for severance pay	(6,614)	5,229
Refund liability	107,088
Inventory	(120,978)
Net cash used in operating activities	(1,809,151)	(1,065,582)
Cash flow from investing activities:
Severance pay fund	3,485	(1,592)
Purchase of fixed assets	(31,999)	(4,170)
Investment in long-term deposit		(6,059)
Net cash used in investing activities	(28,514)	(11,821)
Cash flow from financing activities:
Proceeds from issuance of common stock	1,592,000	878,250
Proceeds from stock to be issued	30,000
Net cash provided by financing activities	1,622,000	878,250
Effect of exchange rates on cash and cash equivalents	10,342	8,394
Decrease in cash and cash equivalents	(205,323)	(190,759)
Cash and cash equivalents - beginning of period	589,818	275,041
Cash and cash equivalents - end of period	384,495	84,282
Non-cash financing activity during the period:
Issuance of common stock and warrants		$ 194,995

XML 21 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Nature of Operations and Summary of Significant Accounting Policies

NOTE 1: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Nature of operations

Going Concern

B. Summary of significant accounting policies

The accounting policies adopted are consistent with those of the previous financial year.

Basis of Presentation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of TechCare, and its subsidiary, Novomic. All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

The Company derives revenues from sales of its product Novokid directly or indirectly through its distributors in the Netherlands and in Israel.

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer.
	●	Identification of the performance obligations in the contract.
	●	Determination of the transaction price.
	●	Allocation of the transaction price to the performance obligations in the contract.
	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.

XML 22 R7.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

9 Months Ended

Sep. 30, 2018

Accounting Changes and Error Corrections [Abstract]

New Accounting Pronouncements

NOTE 2: NEW ACCOUNTING PRONOUNCEMENTS

Accounting Pronouncements Adopted in Current Period

Recently Issued Accounting Pronouncements Not Yet Adopted

XML 23 R8.htm IDEA: XBRL DOCUMENT

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements

9 Months Ended

Sep. 30, 2018

Accounting Changes and Error Corrections [Abstract]

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements

NOTE 3: RESTATEMENT OF 2017 CONDENSED CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS

Condensed consolidated balance sheet as of September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Assets
Current assets:
Cash and cash equivalents	$	84,282						84,282
Other receivables		160,620			29,755			190,375
Total current assets		244,902			29,755			274,657

Non-current assets:
Severance pay fund		10,403						10,403
Long-term deposit		12,071						12,071
Property and equipment, net		99,744						99,744
Total non-current assets		122,218						122,218
Total assets	$	367,120			29,755			396,875

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	137,780						137,780
Option liability		182,720						182,720
Note payable		87,192						87,192
Total current liabilities		407,692						407,692

Non-current liability:
Liability for severance pay		21,184						21,184
Total liabilities		428,876						428,876

Commitments

Stockholders’ equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017		-						-
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017		2,177						2,177
Accumulated other comprehensive income		107,061						107,061
Additional paid-in capital		6,970,542			(943,901	)		6,026,641
Stock to be issued		48,964						48,964
Accumulated deficit		(7,190,500	)		973,656			(6,216,844	)
Total capital deficiency		(61,756	)		29,755			(32,001	)
Total liabilities and capital deficiency	$	367,120			29,755			396,875

Condensed consolidated statement of operations and comprehensive loss for the nine month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		872,874			(609,606	)		263,268
Change in fair value of option liability		182,720						182,720
Marketing, general and administrative expenses		2,441,860			(359,202	)		2,082,658
Operating loss		3,497,454			(968,808	)		2,528,646

Financial income, net		24,495						24,495

Loss before income taxes		3,472,959			(968,808	)		2,504,151
Tax expenses		4,848			(4,848	)		-
Net loss	$	3,477,807			(973,656	)		2,504,151

Net loss per common stock:
Basic	$	(0.16	)		0.04			(0.12	)
Diluted	$	(0.16	)		0.04			(0.12	)

Weighted average number of common stock outstanding:
Basic		21,722,199						21,722,199
Diluted		21,722,199						21,722,199

Comprehensive loss:
Net loss		3,477,807			(973,656	)		2,504,151
Other comprehensive income attributable to foreign currency translation		10,058						10,058
Comprehensive loss		3,467,749			(973,656	)		2,494,093

Condensed consolidated statement of operations and comprehensive loss for the three month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		131,765			(48,735	)		83,030
Change in fair value of option liability		(93,430	)					(93,430	)
Marketing, general and administrative expenses		361,342			37,538			398,880
Operating loss		399,677			(11,197	)		388,480

Financial income, net		5,304						5,304

Loss before income taxes		394,373			(11,197	)		383,176
Tax expenses		-						-
Net loss	$	394,373			(11,197	)		383,176

Net loss per common stock:
Basic	$	(0.018	)		-			(0.018	)
Diluted	$	(0.022	)		-			(0.022	)

Weighted average number of common stock outstanding:
Basic		21,752,409						21,752,409
Diluted		22,018,967						22,018,967

Comprehensive loss:
Net loss		394,373			(11,197	)		383,176
Other comprehensive expense attributable to foreign currency translation		2,344						2,344
Comprehensive loss		396,717			(11,197	)		385,520

XML 24 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' Equity

NOTE 4: STOCKHOLDERS’ EQUITY

Share capital

During the nine months ended September 30, 2018, the Company entered into several agreements, under which the Company raised an aggregate amount of $ 1,622,000, as follows:

	a)	1,291,990 shares of its common stock at a purchase price of $0.387 for a total consideration of $500,000 and warrants to purchase up to 645,995 stock with an exercise price of $0.387, exercisable until June 30, 2018. The warrants expired on June 30, 2018.

	b)	1,033,592 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $400,000, and warrants to purchase up to 516,796 stock with an exercise price of $0.387, exercisable until September 30, 2018. The warrants expired on September 30, 2018.

	c)	108,527 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $42,000, and warrants to purchase up to 70,000 stock with an exercise price of $0.60, exercisable until June 17, 2019.

Investment agreements signed during the three months ended September 30, 2018:

	d)	645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until June 27, 2019.

	e)	645,995 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $250,000, and warrants to purchase up to 416,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	f)	129,199 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $50,000, and warrants to purchase up to 83,333 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	g)	258,398 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $100,000, and warrants to purchase up to 166,667 stock with an exercise price of $0.6, exercisable until August 7, 2019.

	h)	77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 shares of common stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet issued the shares of common stock and, therefore, recorded stock to be issued in the amount of $30,000 in the consolidated financial statements.

	i)	77,519 shares of common stock of the Company at a purchase price of $0.387 for a total consideration of $30,000, and warrants to purchase up to 50,000 stock with an exercise price of $0.6, exercisable until August 21, 2019. As of September 30, 2018, the Company had not yet received the investment proceeds and therefore had not issued the shares of common stock for such investment.

Stock-Based Compensation to employees and directors

During the nine months ended September 30, 2018 the Company had not granted any options to employees and directors.

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2.5-5
Dividend yield	-

A summary of the stock option activity for employees and directors for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		2,640,334		0.0001
Granted		-		-
Options outstanding at September 30, 2018		2,640,334		0.0001
Options exercisable at September 30, 2018		2,640,334		0.0001

Stock-based compensation expenses related to employee awards, included in the Company’s statements of operations and comprehensive loss, were allocated as follows:

	Nine months ended September 30, 2018		Nine months ended September 30, 2017
			Restated (see note 3)
Research and development expenses	$	-		103,795
Marketing ,general and administrative		-		1,119,125
	$	-		1,222,920

Stock-Based Compensation to non-employees – Options and Warrants

In the second quarter of 2018, as part of consulting agreements, the Company granted options to non-employees, as follows:

	1)	83,393 options exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on December 1, 2018, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

	2)	83,393 options to a related party exercisable to purchase 83,393 shares of common stock of the Company, at an exercise price of $0.0001 per option. The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on January 1, 2019, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.

	3)	436,349 options to a related party exercisable to purchase 436,349 shares of common stock of the Company, at an exercise price of $0.387 per option. The options will be vested in accordance with the following vesting periods: 33.33% of the options will be exercisable on January 1, 2019, and the remaining 66.67% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 8 quarters.

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	2.65%-2.85	%
Expected shares price volatility	70	%
Expected option term (years)	5
Dividend yield	-

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2-5
Dividend yield	-

A summary of the stock option activity related to non-employees, for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		621,065		0.2416
Granted		603,135		0.2800
Options outstanding at September 30, 2018		1,224,200		0.2605
Options exercisable at September 30, 2018		621,065		0.2416

XML 25 R10.htm IDEA: XBRL DOCUMENT

OEM Distribution Agreement

9 Months Ended

Sep. 30, 2018

Contractors [Abstract]

OEM Distribution Agreement

NOTE 5: OEM DISTRIBUTION AGREEMENT

As of the date of these financial statements, an FDA approval was not obtained, hence, the Company did not generate any revenues from the OEM agreement.

The fair value of the option as of June 23, 2017 (initial recognition) amounted to $432,518.The key assumptions used in the options’ valuation was as follows:

Risk-free interest rate	1.14	%
Expected shares price volatility	70	%
Expected option term (years)	0.56
Dividend yield	-

The fair value of the option as of December 31, 2017 amounted to $132,470.The key assumptions used in the options’ valuation was as follows:

Risk-free interest rate	1.28	%
Expected shares price volatility	70	%
Expected option term (years)	0.04
Dividend yield	-

The option expired on January 15, 2018.

XML 26 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 6: INCOME TAXES

a. Basis of taxation

The Company and its subsidiary are taxed under the domestic tax laws of the jurisdiction of incorporation of each entity (United States and Israel).

b. Carryforward Tax Losses

c. Corporate tax rates

The regular corporate tax rate in Israel in 2017 is 24% and 23% in 2018.

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “TCJA”), which among other reduces the federal corporate tax rate from 35% to 21%, effective January 1, 2018.

The Company has no impact of the TCJA on these condensed consolidated financial statements.

XML 27 R12.htm IDEA: XBRL DOCUMENT

Loss Per Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Loss Per Share

NOTE 7: LOSS PER SHARE

Loss per share is based on the loss that is attributed to the stockholders holding common stock, divided by the weighted average number of common stock in issue during the period.

XML 28 R13.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

NOTE 8: FAIR VALUE OF FINANCIAL INSTRUMENTS

The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:

	2018			2017
	US dollar			US dollar
Fair value as of January 1	$	132,470			-
Change in fair value recognized in statement of operations and comprehensive loss		(132,470	)		276,150
Fair value as of September 30	$	-			276,150

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 29 R14.htm IDEA: XBRL DOCUMENT

Related Parties

9 Months Ended

Sep. 30, 2018

Related Parties

NOTE 9: RELATED PARTIES

	(a)	On June 28, 2018 the Company entered into a subscription agreement with an investor, pursuant to which the Company will issue 645,995 shares of its common stock at a purchase price of $0.387 for a total consideration of $250,000 and warrants to purchase up to 416,667 stock with an exercise price of $0.60, exercisable until June 28, 2019. In August 2018, the funds were received and the shares of common stock were issued.

	(b)	On August 8, 2018 the Company entered into subscription agreements with several investors who are related parties, pursuant to which the Company issued 904,393 shares of its common stock at a purchase price of $0.387 for a total consideration of $350,000 and warrants to purchase up to 583,334 stock with an exercise price of $0.60, exercisable until August 7, 2019.

	(c)	On July 16, 2018, the Board of Directors of the Company has appointed Mr. Doron Biran as the new Chief Executive Officer of the Company and its wholly-owned subsidiary Novomic. Pursuant to the service agreement (the “Agreement”) signed with Mr, Biran, Mr. Biran will receive a monthly compensation of NIS 52 thousand (approximately $14.3 thousand) plus VAT. In the event of a capital raise exceeding $1,000 thousand Mr. Biran will be entitled to compensation increase to a total of NIS 65 thousand (approximately $17.9 thousand). Furthermore, upon the earlier of either 24 months from the effective date of the Agreement, or a capital raise exceeding $5,000 thousand and listing of the Company on the Nasdaq Stock Market, Mr. Biran shall become an employee of the Company and shall receive a base salary of NIS 60 thousand as well as NIS 5 thousands for automobile expenses (approximately $16.5 thousand) and other customary social benefits.

		Pursuant to the Agreement, Mr. Biran is entitled to options to purchase 870,958 common stock of the Company (the “Options”). The Options shall vest over a period of four years in quarterly increments, commencing on June 11, 2018, subject to continued provision of services by Mr. Biran in accordance with the Agreement. The Options shall accelerate and become fully vested in the event of a merger or acquisition of the Company at an evaluation exceeding $50 million or in the event that the Company’s traded value exceeds $50 million (each, “Acceleration Event” and together “Acceleration Events”), provided that Mr. Biran provided his services to the Company for a period of at least 12 months prior to the Acceleration Event. The exercise price of each Option shall be $0.279, equal to the volume weighted average price of the Company’s common stock during a 30 days’ period prior to the signing of Mr. Biran’s services Agreement. As of the date of the report Options were not granted yet.

XML 30 R15.htm IDEA: XBRL DOCUMENT

Subsequent Event

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Event

NOTE 10: SUBSEQUENT EVENT

XML 31 R16.htm IDEA: XBRL DOCUMENT

Nature of Operations and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of TechCare, and its subsidiary, Novomic. All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

Revenue Recognition

The Company derives revenues from sales of its product Novokid directly or indirectly through its distributors in the Netherlands and in Israel.

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer.
	●	Identification of the performance obligations in the contract.
	●	Determination of the transaction price.
	●	Allocation of the transaction price to the performance obligations in the contract.
	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

The Company reports revenue net of any revenue based taxes assessed by governmental authorities that are imposed on and concurrent with specific revenue-producing transactions.

XML 32 R17.htm IDEA: XBRL DOCUMENT

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Changes and Error Corrections [Abstract]

Schedule of Restatement to Prior Year Income

Condensed consolidated balance sheet as of September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Assets
Current assets:
Cash and cash equivalents	$	84,282						84,282
Other receivables		160,620			29,755			190,375
Total current assets		244,902			29,755			274,657

Non-current assets:
Severance pay fund		10,403						10,403
Long-term deposit		12,071						12,071
Property and equipment, net		99,744						99,744
Total non-current assets		122,218						122,218
Total assets	$	367,120			29,755			396,875

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	137,780						137,780
Option liability		182,720						182,720
Note payable		87,192						87,192
Total current liabilities		407,692						407,692

Non-current liability:
Liability for severance pay		21,184						21,184
Total liabilities		428,876						428,876

Commitments

Stockholders’ equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017		-						-
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017		2,177						2,177
Accumulated other comprehensive income		107,061						107,061
Additional paid-in capital		6,970,542			(943,901	)		6,026,641
Stock to be issued		48,964						48,964
Accumulated deficit		(7,190,500	)		973,656			(6,216,844	)
Total capital deficiency		(61,756	)		29,755			(32,001	)
Total liabilities and capital deficiency	$	367,120			29,755			396,875

Condensed consolidated statement of operations and comprehensive loss for the nine month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		872,874			(609,606	)		263,268
Change in fair value of option liability		182,720						182,720
Marketing, general and administrative expenses		2,441,860			(359,202	)		2,082,658
Operating loss		3,497,454			(968,808	)		2,528,646

Financial income, net		24,495						24,495

Loss before income taxes		3,472,959			(968,808	)		2,504,151
Tax expenses		4,848			(4,848	)		-
Net loss	$	3,477,807			(973,656	)		2,504,151

Net loss per common stock:
Basic	$	(0.16	)		0.04			(0.12	)
Diluted	$	(0.16	)		0.04			(0.12	)

Weighted average number of common stock outstanding:
Basic		21,722,199						21,722,199
Diluted		21,722,199						21,722,199

Comprehensive loss:
Net loss		3,477,807			(973,656	)		2,504,151
Other comprehensive income attributable to foreign currency translation		10,058						10,058
Comprehensive loss		3,467,749			(973,656	)		2,494,093

Condensed consolidated statement of operations and comprehensive loss for the three month period ended September 30, 2017 (Unaudited):

	As previously reported			Adjustments			As Restated
Research and development expenses		131,765			(48,735	)		83,030
Change in fair value of option liability		(93,430	)					(93,430	)
Marketing, general and administrative expenses		361,342			37,538			398,880
Operating loss		399,677			(11,197	)		388,480

Financial income, net		5,304						5,304

Loss before income taxes		394,373			(11,197	)		383,176
Tax expenses		-						-
Net loss	$	394,373			(11,197	)		383,176

Net loss per common stock:
Basic	$	(0.018	)		-			(0.018	)
Diluted	$	(0.022	)		-			(0.022	)

Weighted average number of common stock outstanding:
Basic		21,752,409						21,752,409
Diluted		22,018,967						22,018,967

Comprehensive loss:
Net loss		394,373			(11,197	)		383,176
Other comprehensive expense attributable to foreign currency translation		2,344						2,344
Comprehensive loss		396,717			(11,197	)		385,520

XML 33 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Employees and Directors [Member]

Schedule of Fair Values of Stock Options

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2.5-5
Dividend yield	-

Schedule of Stock Option Activity

A summary of the stock option activity for employees and directors for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		2,640,334		0.0001
Granted		-		-
Options outstanding at September 30, 2018		2,640,334		0.0001
Options exercisable at September 30, 2018		2,640,334		0.0001

Schedule of Stock-based Compensation Expenses Related to Employee Awards

Stock-based compensation expenses related to employee awards, included in the Company’s statements of operations and comprehensive loss, were allocated as follows:

	Nine months ended September 30, 2018		Nine months ended September 30, 2017
			Restated (see note 3)
Research and development expenses	$	-		103,795
Marketing ,general and administrative		-		1,119,125
	$	-		1,222,920

Non Employees [Member]

Schedule of Fair Values of Stock Options

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	2.65%-2.85	%
Expected shares price volatility	70	%
Expected option term (years)	5
Dividend yield	-

The following assumptions were applied in determining the options’ fair value on their grant date:

Risk-free interest rate	1.54	%
Expected shares price volatility	70	%
Expected option term (years)	2-5
Dividend yield	-

Schedule of Stock Option Activity

A summary of the stock option activity related to non-employees, for the nine months ended September 30, 2018:

	Number of Options		Weighted Average Exercise Price
			U.S Dollar
Options outstanding at December 31, 2017		621,065		0.2416
Granted		603,135		0.2800
Options outstanding at September 30, 2018		1,224,200		0.2605
Options exercisable at September 30, 2018		621,065		0.2416

XML 34 R19.htm IDEA: XBRL DOCUMENT

OEM Distribution Agreement (Tables)

9 Months Ended

Sep. 30, 2018

Contractors [Abstract]

Schedule of Assumptions Used to Fair Values of Options Valuation

Risk-free interest rate	1.14	%
Expected shares price volatility	70	%
Expected option term (years)	0.56
Dividend yield	-

Risk-free interest rate	1.28	%
Expected shares price volatility	70	%
Expected option term (years)	0.04
Dividend yield	-

XML 35 R20.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Reconciliation of Change Fair Value Measurement Estimated Utilizing Level 3 Inputs

The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:

	2018			2017
	US dollar			US dollar
Fair value as of January 1	$	132,470			-
Change in fair value recognized in statement of operations and comprehensive loss		(132,470	)		276,150
Fair value as of September 30	$	-			276,150

XML 36 R21.htm IDEA: XBRL DOCUMENT

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Accounting Policies [Abstract]
Comprehensive loss	$ 664,933	$ 385,520	$ 1,507,925	$ 2,494,093
Accumulated losses	$ 8,086,011	$ 6,216,844	$ 8,086,011	$ 6,216,844	$ 6,571,083

XML 37 R22.htm IDEA: XBRL DOCUMENT

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Stock compensation expense	$ 943,901	$ 27,544	$ 1,222,920

XML 38 R23.htm IDEA: XBRL DOCUMENT

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements - Schedule of Restatement to Prior Year Income (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 384,495	$ 84,282	$ 384,495	$ 84,282	$ 589,818	$ 275,041
Other receivables	244,212	190,375	244,212	190,375	105,818
Total current assets	958,573	274,657	958,573	274,657	740,399
Severance pay fund	21,564	10,403	21,564	10,403	13,764
Long-term deposit	11,745	12,071	11,745	12,071	12,287
Property and equipment, net	133,365	99,744	133,365	99,744	95,984
Total non-current assets	166,674	122,218	166,674	122,218	122,035
Total assets	1,125,247	396,875	1,125,247	396,875	862,434
Accounts payable and accrued expenses	252,376	137,780	252,376	137,780	106,362
Option liability		182,720		182,720
Note payable	84,719	87,192	84,719	87,192	88,751
Total current liabilities	444,555	407,692	444,555	407,692	327,583
Liability for severance pay	27,642	21,184	27,642	21,184	23,422
Total liabilities	472,197	428,876	472,197	428,876	351,005
Commitments
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017	2,995	2,177	2,995	2,177	2,584
Accumulated other comprehensive income	111,780	107,061	111,780	107,061	104,777
Additional paid-in capital	8,564,286	6,026,641	8,564,286	6,026,641	6,945,151
Stock to be issued	60,000	48,964	60,000	48,964	30,000
Accumulated deficit	(8,086,011)	(6,216,844)	(8,086,011)	(6,216,844)	(6,571,083)
Total capital deficiency	653,050	(32,001)	653,050	(32,001)	511,429
Total liabilities and capital deficiency	1,125,247	396,875	1,125,247	396,875	$ 862,434
Research and development expenses	143,400	83,030	191,316	263,268
Change in fair value of option liability		(93,430)	(132,470)	182,720
Marketing, general and administrative expenses	522,864	398,880	1,489,784	2,082,658
Operating loss	$ 647,121	388,480	$ 1,488,663	2,528,646
Financial income, net		5,304		24,495
Loss before income taxes		383,176		2,504,151
Tax expenses
Net loss per common stock: Basic	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.12)
Net loss per common stock: Diluted	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.12)
Weighted average number of common stock outstanding: Basic	32,529,717	21,752,409	31,709,944	21,722,199
Weighted average number of common stock outstanding: Diluted	32,529,717	22,018,967	31,807,036	21,722,199
Net loss	$ 656,231	$ 383,176	$ 1,514,928	$ 2,504,151
Other comprehensive income attributable to foreign currency translation	(8,702)	(2,344)	7,003	10,058
Comprehensive loss	$ 664,933	385,520	$ 1,507,925	2,494,093
As Previously Reported [Member]
Cash and cash equivalents		84,282		84,282
Other receivables		160,620		160,620
Total current assets		244,902		244,902
Severance pay fund		10,403		10,403
Long-term deposit		12,071		12,071
Property and equipment, net		99,744		99,744
Total non-current assets		122,218		122,218
Total assets		367,120		367,120
Accounts payable and accrued expenses		137,780		137,780
Option liability		182,720		182,720
Note payable		87,192		87,192
Total current liabilities		407,692		407,692
Liability for severance pay		21,184		21,184
Total liabilities		428,876		428,876
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized: none issued and outstanding at September 30, 2017
Common stock, par value $0.0001 per share, 500,000,000 shares authorized: 21,776,762 shares issued and outstanding at September 30, 2017		2,177		2,177
Accumulated other comprehensive income		107,061		107,061
Additional paid-in capital		6,970,542		6,970,542
Stock to be issued		48,964		48,964
Accumulated deficit		(7,190,500)		(7,190,500)
Total capital deficiency		(61,756)		(61,756)
Total liabilities and capital deficiency		367,120		367,120
Research and development expenses		131,765		872,874
Change in fair value of option liability		(93,430)		182,720
Marketing, general and administrative expenses		361,342		2,441,860
Operating loss		399,677		3,497,454
Financial income, net		5,304		24,495
Loss before income taxes		394,373		3,472,959
Tax expenses				$ 4,848
Net loss per common stock: Basic		$ (0.018)		$ (0.16)
Net loss per common stock: Diluted		$ (0.022)		$ (0.16)
Weighted average number of common stock outstanding: Basic		21,752,409		21,722,199
Weighted average number of common stock outstanding: Diluted		22,018,967		21,722,199
Net loss		$ 394,373		$ 3,477,807
Other comprehensive income attributable to foreign currency translation		2,344		10,058
Comprehensive loss		396,717		3,467,749
Adjustment [Member]
Other receivables		29,755		29,755
Total current assets		29,755		29,755
Total assets		29,755		29,755
Additional paid-in capital		(943,901)		(943,901)
Accumulated deficit		973,656		973,656
Total capital deficiency		29,755		29,755
Total liabilities and capital deficiency		29,755		29,755
Research and development expenses		(48,735)		(609,606)
Marketing, general and administrative expenses		37,538		(359,202)
Operating loss		(11,197)		(968,808)
Loss before income taxes		$ (11,197)		(968,808)
Tax expenses				$ (4,848)
Net loss per common stock: Basic				$ 0.04
Net loss per common stock: Diluted				$ 0.04
Net loss		$ (11,197)		$ (973,656)
Comprehensive loss		$ (11,197)		$ (973,656)

XML 39 R24.htm IDEA: XBRL DOCUMENT

Restatement of 2017 Condensed Consolidated Quarterly Financial Statements - Schedule of Restatement to Prior Year Income (Details) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	29,949,096	25,835,401	21,776,762
Common stock, shares outstanding	29,949,096	25,835,401	21,776,762

XML 40 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Mar. 31, 2017	Sep. 30, 2018	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 31, 2017
Proceeds from share capital, aggregate amount				$ 1,622,000
Stock-based compensation			$ 943,901	$ 27,544	$ 1,222,920
Employees [Member]
Number of shares granted	869,596
Options exercise price	$ 0.0001
Options granted exercisable term	2 years 6 months
Non-Employees [Member]
Number of warrants exercisable to purchase common stock						100,000
Warrants exercisable, exercise price per share						$ 1.50
Number of shares granted	521,065			603,135
Options exercise price	$ 0.0001			$ 0.2800
Options granted exercisable term	5 years
Common Stock [Member]
Number of common stock shares issued for consideration				1,291,990
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration				$ 500,000
Number of warrants exercisable to purchase common stock		645,995		645,995
Warrants exercisable, exercise price per share		$ 0.387		$ 0.387
Warrants exercisable, expiry date				Jun. 30, 2018
Common Stock One [Member]
Number of common stock shares issued for consideration				1,033,592
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration				$ 400,000
Number of warrants exercisable to purchase common stock		516,796		516,796
Warrants exercisable, exercise price per share		$ 0.387		$ 0.387
Warrants exercisable, expiry date				Sep. 30, 2018
Common Stock Two [Member]
Number of common stock shares issued for consideration				108,527
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration				$ 42,000
Number of warrants exercisable to purchase common stock		70,000		70,000
Warrants exercisable, exercise price per share		$ 0.60		$ 0.60
Warrants exercisable, expiry date				Jun. 17, 2019
Investment Agreements [Member] \| Common Stock [Member]
Number of common stock shares issued for consideration		645,995
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 250,000
Number of warrants exercisable to purchase common stock		416,667		416,667
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Jun. 27, 2019
Investment Agreements [Member] \| Common Stock One [Member]
Number of common stock shares issued for consideration		645,995
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 250,000
Number of warrants exercisable to purchase common stock		416,667		416,667
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Aug. 07, 2019
Investment Agreements [Member] \| Common Stock Two [Member]
Number of common stock shares issued for consideration		129,199
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 50,000
Number of warrants exercisable to purchase common stock		83,333		83,333
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Aug. 07, 2019
Investment Agreements [Member] \| Common Stock Three [Member]
Number of common stock shares issued for consideration		258,398
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 100,000
Number of warrants exercisable to purchase common stock		166,667		166,667
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Aug. 07, 2019
Investment Agreements [Member] \| Common Stock Four [Member]
Number of common stock shares issued for consideration		77,519
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 30,000
Number of warrants exercisable to purchase common stock		50,000		50,000
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Aug. 21, 2019
Stock to be issued		$ 30,000		$ 30,000
Investment Agreements [Member] \| Common Stock Five [Member]
Number of common stock shares issued for consideration		77,519
Shares issued price per share		$ 0.387		$ 0.387
Number of common stock issued for consideration		$ 30,000
Number of warrants exercisable to purchase common stock		50,000		50,000
Warrants exercisable, exercise price per share		$ 0.6		$ 0.6
Warrants exercisable, expiry date		Aug. 21, 2019
Consulting Agreement [Member] \| Non-Employees [Member]
Number of shares granted		83,393
Options exercise price		$ 0.0001
Stock based compensation vesting rights		The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on December 1, 2018, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.
Share based compensation vesting percentage		25.00%
Consulting Agreement One [Member] \| Non-Employees [Member]
Number of shares granted		83,393
Options exercise price		$ 0.0001
Stock based compensation vesting rights		The options will be vested in accordance with the following vesting periods: 25% of the options will be exercisable on January 1, 2019, and the remaining 75% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 12 quarters.
Share based compensation vesting percentage		25.00%
Consulting Agreement Two [Member] \| Non-Employees [Member]
Number of shares granted		436,349
Options exercise price		$ 0.387
Stock based compensation vesting rights		The options will be vested in accordance with the following vesting periods: 33.33% of the options will be exercisable on January 1, 2019, and the remaining 66.67% will be considered exercisable at the end of each subsequent three-month period thereafter, over the course of 8 quarters.
Share based compensation vesting percentage		33.33%

XML 41 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Fair Values of Stock Options (Details)		1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 23, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Risk-free interest rate	1.14%				1.28%
Expected shares price volatility	70.00%				70.00%
Expected option term (years)	6 months 21 days				15 days
Dividend yield	0.00%				0.00%
Employees and Directors [Member]
Risk-free interest rate				1.54%
Expected shares price volatility				70.00%
Dividend yield				0.00%
Employees and Directors [Member] \| Minimum [Member]
Expected option term (years)				2 years 6 months
Employees and Directors [Member] \| Maximum [Member]
Expected option term (years)				5 years
Non Employees [Member]
Expected shares price volatility			70.00%
Expected option term (years)			5 years
Dividend yield			0.00%
Non Employees [Member] \| Minimum [Member]
Risk-free interest rate			2.65%
Non Employees [Member] \| Maximum [Member]
Risk-free interest rate			2.85%
Non-Employees [Member]
Risk-free interest rate		1.54%
Expected shares price volatility		70.00%
Dividend yield		0.00%
Non-Employees [Member] \| Minimum [Member]
Expected option term (years)		2 years
Non-Employees [Member] \| Maximum [Member]
Expected option term (years)		5 years

XML 42 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Option Activity (Details) - $ / shares	1 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2018
Employees and Directors [Member]
Number of Options outstanding, beginning balance		2,640,334
Number of Options, Granted
Number of Options, outstanding, ending balance		2,640,334
Options exercisable, ending balance		2,640,334
Weighted Average Exercise Price outstanding, beginning balance		$ 0.0001
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, ending balance		0.0001
Weighted Average Exercise Price, Options exercisable		$ 0.0001
Non-Employees [Member]
Number of Options outstanding, beginning balance		621,065
Number of Options, Granted	521,065	603,135
Number of Options, outstanding, ending balance		1,224,200
Options exercisable, ending balance		621,065
Weighted Average Exercise Price outstanding, beginning balance		$ 0.2416
Weighted Average Exercise Price, Granted	$ 0.0001	0.2800
Weighted Average Exercise Price, ending balance		0.2605
Weighted Average Exercise Price, Options exercisable		$ 0.2416

XML 43 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-based Compensation Expenses Related to Employee Awards (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation	$ 943,901	$ 27,544	$ 1,222,920
Research and Development Expense [Member]
Stock-based compensation			103,795
Marketing, General and Administrative Expenses [Member]
Stock-based compensation			$ 1,119,125

XML 44 R29.htm IDEA: XBRL DOCUMENT

OEM Distribution Agreement (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
	Jun. 23, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Common stock purchase consideration		$ 1,592,000	$ 878,250
Fair value of option			$ 194,995
OEM Agreement [Member] \| OEM Distributor [Member]
Royalty advance paid		10,000
Escrow deposit		$ 140,000
Options granted to purchase shares of common stock, percentage		9.09%
Common stock purchase consideration		$ 900,000
Options expiration term		Jan. 15, 2018
Fair value of option	$ 432,518			$ 132,470

XML 45 R30.htm IDEA: XBRL DOCUMENT

OEM Distribution Agreement - Schedule of Assumptions Used to Fair Values of Options Valuation (Details)		12 Months Ended
	Jun. 23, 2017	Dec. 31, 2017
Contractors [Abstract]
Risk-free interest rate	1.14%	1.28%
Expected shares price volatility	70.00%	70.00%
Expected option term (years)	6 months 21 days	15 days
Dividend yield	0.00%	0.00%

XML 46 R31.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)		9 Months Ended	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Sep. 30, 2018	Dec. 31, 2017
Net operating carry forward		$ 400,000
Income tax reconciliation description		Federal corporate tax rate from 35% to 21%, effective January 1, 2018.
January 1, 2018 [Member]
Corporate tax rate	21.00%
Israel Tax [Member]
Net operating carry forward		$ 5,100,000
Corporate tax rate		23.00%	24.00%

XML 47 R32.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Schedule of Reconciliation of Change Fair Value Measurement Estimated Utilizing Level 3 Inputs (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair value, beginning balance	$ 132,470
Change in fair value recognized in statement of operations and comprehensive loss	(132,470)	276,150
Fair value ending balance		$ 276,150

XML 48 R33.htm IDEA: XBRL DOCUMENT

Related Parties (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended	9 Months Ended
Related Parties (Details Narrative) - USD ($)	Aug. 08, 2018	Jul. 16, 2018	Jun. 28, 2018	Aug. 31, 2018	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Monthly compensation					$ 943,901	$ 27,544	$ 1,222,920
Board of Directors [Member]
Stock option purchase, shares		870,958
Stock option vesting period		4 years
Trading value of acceleration events		$ 50,000,000
Stock option exercise price per shares		$ 0.279
Subscription Agreement [Member]
Number of common stock shares issued for consideration				645,995
Subscription Agreement [Member] \| Three Investors [Member]
Number of common stock shares issued for consideration	904,393		645,995
Shares issued price per share	$ 0.387		$ 0.387
Number of common stock issued for consideration	$ 350,000		$ 250,000
Number of warrants exercisable to purchase common stock	583,334		416,667
Warrants exercisable, exercise price per share	$ 0.60		$ 0.60
Warrants exercisable, expiry date	Aug. 07, 2019		Jun. 28, 2019
Service Agreement [Member] \| Mr. Biran [Member]
Monthly compensation		$ 14,300
Capital raise exceeding		1,000
Service Agreement [Member] \| Mr. Biran [Member] \| Automobile Expenses And Other Customary Social Benefits [Member]
Monthly compensation		16,500
Capital raise exceeding		5,000
Service Agreement [Member] \| Mr. Biran [Member] \| Maximum [Member]
Monthly compensation		17,900
Service Agreement [Member] \| Mr. Biran [Member] \| Israel, New Shekels [Member]
Monthly compensation		52,000
Service Agreement [Member] \| Mr. Biran [Member] \| Israel, New Shekels [Member] \| Automobile Expenses And Other Customary Social Benefits [Member]
Monthly compensation		5,000
Basic salary		60,000
Service Agreement [Member] \| Mr. Biran [Member] \| Israel, New Shekels [Member] \| Maximum [Member]
Monthly compensation		$ 65,000

XML 49 R34.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details Narrative) - USD ($)		1 Months Ended
Subsequent Event (Details Narrative) - USD ($)	Oct. 28, 2018	Aug. 31, 2018
Subscription Agreement [Member]
Number of common stock shares issues		645,995
Subsequent Event [Member]
Initial investment	$ 500,000
Subsequent Event [Member] \| Subscription Agreement [Member]
Initial investment	$ 250,000
Number of common stock shares issues	1,915,708
Shares purchase price per share	$ 0.261
Warrant exercise price per share	$ 0.6
Warrant exercisable date	Oct. 27, 2019
Subsequent Event [Member] \| Subscription Agreement [Member] \| Maximum [Member]
Warrant to purchase shares of common stock	416,667

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end